{
    "6432fc0457b1c7a31500001f_0": [
        {
            "start_logit": 14.7265625,
            "end_logit": 12.96875,
            "text": "SERPING1 gene",
            "probability": 1.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -0.124267578125,
            "text": "SERPING1 gene resulting in a deficiency in functional plasma C1 esterase inhibitor (C1EI",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -1.3291015625,
            "text": "SERPING1 gene resulting in a deficiency in functional plasma C1 esterase inhibitor (C1",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -2.291015625,
            "text": "SERPING1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -4.33984375,
            "text": "SERPING1 gene resulting in a deficiency in functional plasma C1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -4.91796875,
            "text": "SERPING1 gene resulting in a deficiency in functional plasma C1 esterase inhibitor (C1EI)",
            "probability": 0.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -5.6953125,
            "text": "SERP",
            "probability": 0.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -6.33984375,
            "text": "SERPING",
            "probability": 0.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -6.67578125,
            "text": "SERPING1 gene resulting in a deficiency in functional plasma C1 esterase",
            "probability": 0.0
        },
        {
            "start_logit": -5.8984375,
            "end_logit": 12.96875,
            "text": "1 gene",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": 12.96875,
            "text": "the SERPING1 gene",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 12.96875,
            "text": "gene",
            "probability": 0.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -9.1640625,
            "text": "SERPING1 gene resulting in a deficiency in functional plasma C1 esterase inhibitor (C1EI), a serine protease",
            "probability": 0.0
        },
        {
            "start_logit": -7.53125,
            "end_logit": 12.96875,
            "text": "ING1 gene",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 12.96875,
            "text": "HAE are caused by mutations in the SERPING1 gene",
            "probability": 0.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -10.3203125,
            "text": "SERPING1 gene resulting in a deficiency in functional plasma C1 esterase inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -10.8203125,
            "text": "SERPING1 gene resulting in a deficiency in functional plasma C1 esterase inhibitor (C1EI), a",
            "probability": 0.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -11.1875,
            "text": "SERPING1 gene resulting in a deficiency in functional plasma",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 12.96875,
            "text": "Almost all cases of HAE are caused by mutations in the SERPING1 gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 12.96875,
            "text": "of HAE are caused by mutations in the SERPING1 gene",
            "probability": 0.0
        }
    ],
    "63f03c47f36125a42600001e_0": [
        {
            "start_logit": 8.8984375,
            "end_logit": 10.21875,
            "text": "Convidecia",
            "probability": 1.0
        },
        {
            "start_logit": -6.51953125,
            "end_logit": 10.21875,
            "text": "cia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -5.32421875,
            "text": "Convideci",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 10.21875,
            "text": "a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 10.21875,
            "text": "idecia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.5078125,
            "end_logit": 10.21875,
            "text": "adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 10.21875,
            "text": "COVID-19 vaccine (Convidecia",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 10.21875,
            "text": "vaccine (Convidecia",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 10.21875,
            "text": "and protein-subunit-based COVID-19 vaccine (Convidecia",
            "probability": 0.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.453125,
            "text": "Conv",
            "probability": 0.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.5078125,
            "text": "Convide",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 10.21875,
            "text": "protein-subunit-based COVID-19 vaccine (Convidecia",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 10.21875,
            "text": "boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 10.21875,
            "text": "an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 10.21875,
            "text": "immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 10.21875,
            "text": "ID-19 vaccine (Convidecia",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 10.21875,
            "text": "type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia",
            "probability": 0.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -10.65625,
            "text": "Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.",
            "probability": 0.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -11.0390625,
            "text": "Convidecia/ZF2001):",
            "probability": 0.0
        },
        {
            "start_logit": -6.51953125,
            "end_logit": -5.32421875,
            "text": "ci",
            "probability": 0.0
        }
    ],
    "63f03c47f36125a42600001e_1": [
        {
            "start_logit": 10.7734375,
            "end_logit": 12.2421875,
            "text": "Coronavirus Disease 2019",
            "probability": 1.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": 3.22265625,
            "text": "Coronavirus Disease",
            "probability": 0.0001214742660522461
        },
        {
            "start_logit": -4.9765625,
            "end_logit": 12.2421875,
            "text": "2019",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.53125,
            "end_logit": 12.2421875,
            "text": "Disease 2019",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -6.109375,
            "text": "Coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.2421875,
            "text": "adenovirus type-5-vectored Coronavirus Disease 2019",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 12.2421875,
            "text": "immunization with a recombinant adenovirus type-5-vectored Coronavirus Disease 2019",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -9.8125,
            "text": "Coronavirus Disease 2019 (COVID-19) vaccine",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -10.015625,
            "text": "Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -11.4296875,
            "text": "Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -11.6796875,
            "text": "Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein-subunit-",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -11.6953125,
            "text": "Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein-subunit",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -11.796875,
            "text": "Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein-",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -11.828125,
            "text": "Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein-subunit-based",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -11.875,
            "text": "Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and",
            "probability": 0.0
        },
        {
            "start_logit": -6.53125,
            "end_logit": 3.22265625,
            "text": "Disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 3.22265625,
            "text": "adenovirus type-5-vectored Coronavirus Disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 3.22265625,
            "text": "immunization with a recombinant adenovirus type-5-vectored Coronavirus Disease",
            "probability": 0.0
        },
        {
            "start_logit": -6.37890625,
            "end_logit": -6.94140625,
            "text": "ZF",
            "probability": 0.0
        },
        {
            "start_logit": -6.37890625,
            "end_logit": -7.65234375,
            "text": "Z",
            "probability": 0.0
        }
    ],
    "63f03c47f36125a42600001e_2": [
        {
            "start_logit": -7.01171875,
            "end_logit": -4.3359375,
            "text": "Convidecia",
            "probability": 0.517578125
        },
        {
            "start_logit": -8.109375,
            "end_logit": -4.3359375,
            "text": "Heterologous boosting with ZF2001 following primary vaccination with Convidecia",
            "probability": 0.171875
        },
        {
            "start_logit": -8.5859375,
            "end_logit": -4.3359375,
            "text": "vaccination with Convidecia",
            "probability": 0.1068115234375
        },
        {
            "start_logit": -9.359375,
            "end_logit": -4.3359375,
            "text": "primary vaccination with Convidecia",
            "probability": 0.04925537109375
        },
        {
            "start_logit": -9.390625,
            "end_logit": -4.3359375,
            "text": "cia",
            "probability": 0.047760009765625
        },
        {
            "start_logit": -9.890625,
            "end_logit": -4.3359375,
            "text": "boosting with ZF2001 following primary vaccination with Convidecia",
            "probability": 0.028961181640625
        },
        {
            "start_logit": -10.015625,
            "end_logit": -4.3359375,
            "text": "a",
            "probability": 0.0255584716796875
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -4.3359375,
            "text": "idecia",
            "probability": 0.013153076171875
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -4.3359375,
            "text": "CONCLUSIONS: Heterologous boosting with ZF2001 following primary vaccination with Convidecia",
            "probability": 0.0129547119140625
        },
        {
            "start_logit": -8.109375,
            "end_logit": -7.12890625,
            "text": "Heterologous boosting",
            "probability": 0.0105743408203125
        },
        {
            "start_logit": -11.2421875,
            "end_logit": -4.3359375,
            "text": "with Convidecia",
            "probability": 0.007495880126953125
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -9.5078125,
            "text": "Convidecia is more immunogenic than a single dose of Convidecia and is not associated with safety concerns.",
            "probability": 0.0029354095458984375
        },
        {
            "start_logit": -9.890625,
            "end_logit": -7.12890625,
            "text": "boosting",
            "probability": 0.0017805099487304688
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -7.12890625,
            "text": "CONCLUSIONS: Heterologous boosting",
            "probability": 0.0007901191711425781
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -11.03125,
            "text": "Convideci",
            "probability": 0.0006351470947265625
        },
        {
            "start_logit": -8.5859375,
            "end_logit": -9.5078125,
            "text": "vaccination with Convidecia is more immunogenic than a single dose of Convidecia and is not associated with safety concerns.",
            "probability": 0.0006060600280761719
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -11.234375,
            "text": "Convidecia is",
            "probability": 0.0005183219909667969
        },
        {
            "start_logit": -8.109375,
            "end_logit": -10.5546875,
            "text": "Heterologous boost",
            "probability": 0.0003452301025390625
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -11.71875,
            "text": "Convide",
            "probability": 0.0003192424774169922
        },
        {
            "start_logit": -9.359375,
            "end_logit": -9.5078125,
            "text": "primary vaccination with Convidecia is more immunogenic than a single dose of Convidecia and is not associated with safety concerns.",
            "probability": 0.0002772808074951172
        }
    ],
    "63f03c47f36125a42600001e_3": [
        {
            "start_logit": 13.765625,
            "end_logit": 14.25,
            "text": "thyroid cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.10546875,
            "end_logit": 14.25,
            "text": "cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.765625,
            "end_logit": -3.09765625,
            "text": "thyroid",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 14.25,
            "text": "SARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 14.25,
            "text": "safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 14.25,
            "text": "CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 14.25,
            "text": "CorV, and ZF2001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 14.25,
            "text": "vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 14.25,
            "text": "BBIBP-CorV, and ZF2001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.25,
            "text": "ZF2001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.25,
            "text": "IBP-CorV, and ZF2001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.25,
            "text": "2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.25,
            "text": "CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 14.25,
            "text": "F2001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 14.25,
            "text": "001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 14.25,
            "text": "P-CorV, and ZF2001) are safe in thyroid cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -11.375,
            "text": "thyroid cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -12.1328125,
            "text": "thyroid cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": -3.09765625,
            "text": "SARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": -3.09765625,
            "text": "safe in thyroid",
            "probability": 0.0
        }
    ],
    "63f03c47f36125a42600001e_4": [
        {
            "start_logit": 12.7109375,
            "end_logit": 5.15625,
            "text": "SARS-CoV-2",
            "probability": 0.87060546875
        },
        {
            "start_logit": 12.7109375,
            "end_logit": 3.251953125,
            "text": "SARS-CoV",
            "probability": 0.12841796875
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -2.400390625,
            "text": "SARS-CoV-2 Delta",
            "probability": 0.0004525184631347656
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -5.25390625,
            "text": "SARS-",
            "probability": 2.5928020477294922e-05
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -5.734375,
            "text": "SARS-CoV-2 Delta variant",
            "probability": 1.609325408935547e-05
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -6.52734375,
            "text": "SARS",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -6.9375,
            "text": "SARS-CoV-2 Delta variant in lethal K18-hAC",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -7.46484375,
            "text": "SARS-CoV-2 Delta variant in lethal K18-hACE2 mice.",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -8.578125,
            "text": "SARS-CoV-",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -9.0078125,
            "text": "SARS-CoV-2 Delta variant in",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -9.1953125,
            "text": "SARS-CoV-2 Delta variant in lethal K18-hACE2",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -9.4375,
            "text": "SARS-CoV-2 Delta variant in lethal K1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -9.6953125,
            "text": "SARS-CoV-2 Delta variant in lethal",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -10.390625,
            "text": "SARS-CoV-2 Delta variant in lethal K18-hACE2 mice",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -10.4765625,
            "text": "SARS-CoV-2 Delta variant in lethal K18-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.12109375,
            "end_logit": 5.15625,
            "text": "CoV-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 5.15625,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": -4.12109375,
            "end_logit": 3.251953125,
            "text": "CoV",
            "probability": 0.0
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 5.15625,
            "text": "-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 5.15625,
            "text": "protection of ZF2001 against the SARS-CoV-2",
            "probability": 0.0
        }
    ],
    "63f03c47f36125a42600001e_5": [
        {
            "start_logit": 7.72265625,
            "end_logit": 10.4296875,
            "text": "SARS-CoV-2 Delta variant-induced severe pneumonia",
            "probability": 0.98828125
        },
        {
            "start_logit": 3.26953125,
            "end_logit": 10.4296875,
            "text": "pneumonia",
            "probability": 0.011505126953125
        },
        {
            "start_logit": 7.72265625,
            "end_logit": -0.4150390625,
            "text": "SARS-CoV-2 Delta",
            "probability": 1.9311904907226562e-05
        },
        {
            "start_logit": -5.01953125,
            "end_logit": 10.4296875,
            "text": "Delta variant-induced severe pneumonia",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 10.4296875,
            "text": "CoV-2 Delta variant-induced severe pneumonia",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.20703125,
            "end_logit": 10.4296875,
            "text": "severe pneumonia",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.796875,
            "end_logit": 10.4296875,
            "text": "2 Delta variant-induced severe pneumonia",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.72265625,
            "end_logit": -4.29296875,
            "text": "SARS-CoV-2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.75,
            "end_logit": 10.4296875,
            "text": "variant-induced severe pneumonia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.72265625,
            "end_logit": -5.0859375,
            "text": "SARS-CoV-2 Delta variant",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 10.4296875,
            "text": "-CoV-2 Delta variant-induced severe pneumonia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.72265625,
            "end_logit": -5.59765625,
            "text": "SARS-CoV",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.72265625,
            "end_logit": -6.578125,
            "text": "SARS-CoV-2 Delta variant-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.72265625,
            "end_logit": -6.66796875,
            "text": "SARS-CoV-2 Delta variant-induced severe",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 10.4296875,
            "text": "conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 10.4296875,
            "text": "vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia",
            "probability": 0.0
        },
        {
            "start_logit": 7.72265625,
            "end_logit": -7.4765625,
            "text": "SARS-",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 10.4296875,
            "text": "to SARS-CoV-2 Delta variant-induced severe pneumonia",
            "probability": 0.0
        },
        {
            "start_logit": 7.72265625,
            "end_logit": -8.4921875,
            "text": "SARS-CoV-",
            "probability": 0.0
        },
        {
            "start_logit": 7.72265625,
            "end_logit": -9.1328125,
            "text": "SARS",
            "probability": 0.0
        }
    ],
    "63f03c47f36125a42600001e_6": [
        {
            "start_logit": 12.8828125,
            "end_logit": 12.5078125,
            "text": "SARS-CoV-2",
            "probability": 1.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -1.0009765625,
            "text": "SARS-CoV",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -4.77734375,
            "end_logit": 12.5078125,
            "text": "CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": -5.46484375,
            "end_logit": 12.5078125,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -6.33984375,
            "text": "SARS-CoV-2.",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -6.359375,
            "text": "SARS",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -6.6171875,
            "text": "SARS-CoV-",
            "probability": 0.0
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 12.5078125,
            "text": "prototype SARS-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -6.73828125,
            "text": "SARS-",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 12.5078125,
            "text": "-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 12.5078125,
            "text": "vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": 12.5078125,
            "text": "-2",
            "probability": 0.0
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 12.5078125,
            "text": ", we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 12.5078125,
            "text": "dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": -8.84375,
            "end_logit": 12.5078125,
            "text": "we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": 12.5078125,
            "text": "receptor-binding domain (RBD) of prototype SARS-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": 12.5078125,
            "text": "protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": 12.5078125,
            "text": "the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 12.5078125,
            "text": "developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 12.5078125,
            "text": "the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2",
            "probability": 0.0
        }
    ],
    "642c82c557b1c7a315000012_0": [
        {
            "start_logit": 15.234375,
            "end_logit": 15.703125,
            "text": "Indian muntjac",
            "probability": 1.0
        },
        {
            "start_logit": 15.234375,
            "end_logit": 0.060882568359375,
            "text": "Indian muntjac, the mammal with the lowest known chromosome number (2n = 6",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 15.234375,
            "end_logit": -3.455078125,
            "text": "Indian muntjac, the mammal with the lowest known chromosome number (2n",
            "probability": 0.0
        },
        {
            "start_logit": -4.14453125,
            "end_logit": 15.703125,
            "text": "female Indian muntjac",
            "probability": 0.0
        },
        {
            "start_logit": -4.89453125,
            "end_logit": 15.703125,
            "text": "c",
            "probability": 0.0
        },
        {
            "start_logit": 15.234375,
            "end_logit": -4.77734375,
            "text": "Indian muntja",
            "probability": 0.0
        },
        {
            "start_logit": 15.234375,
            "end_logit": -5.2734375,
            "text": "Indian",
            "probability": 0.0
        },
        {
            "start_logit": 15.234375,
            "end_logit": -5.27734375,
            "text": "Indian mun",
            "probability": 0.0
        },
        {
            "start_logit": 15.234375,
            "end_logit": -5.55078125,
            "text": "Indian muntjac, the mammal with the lowest known chromosome number (2n =",
            "probability": 0.0
        },
        {
            "start_logit": 15.234375,
            "end_logit": -5.6015625,
            "text": "Indian munt",
            "probability": 0.0
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 15.703125,
            "text": "muntjac",
            "probability": 0.0
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 15.703125,
            "text": "jac",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 15.703125,
            "text": "tjac",
            "probability": 0.0
        },
        {
            "start_logit": 15.234375,
            "end_logit": -8.0,
            "text": "Indian muntjac, the mammal with the lowest known chromosome number (2n = 6),",
            "probability": 0.0
        },
        {
            "start_logit": 15.234375,
            "end_logit": -8.625,
            "text": "Indian muntjac, the mammal",
            "probability": 0.0
        },
        {
            "start_logit": -9.171875,
            "end_logit": 15.703125,
            "text": "Here we used the unique cytological attributes of female Indian muntjac",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 15.703125,
            "text": "used the unique cytological attributes of female Indian muntjac",
            "probability": 0.0
        },
        {
            "start_logit": 15.234375,
            "end_logit": -9.390625,
            "text": "Indian muntjac, the",
            "probability": 0.0
        },
        {
            "start_logit": 15.234375,
            "end_logit": -9.484375,
            "text": "Indian muntjac, the mammal with the lowest known chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 15.234375,
            "end_logit": -10.046875,
            "text": "Indian muntjac, the mammal with the lowest known chromosome number (",
            "probability": 0.0
        }
    ],
    "642c82c557b1c7a315000012_1": [
        {
            "start_logit": 15.5859375,
            "end_logit": 16.375,
            "text": "Indian Muntjac",
            "probability": 1.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -1.4814453125,
            "text": "Indian Muntjac, a Placental Mammal with Only Three",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -2.728515625,
            "text": "Indian Muntjac,",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -3.376953125,
            "text": "Indian Muntjac, a Placental Mammal",
            "probability": 0.0
        },
        {
            "start_logit": -4.55078125,
            "end_logit": 16.375,
            "text": "c",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -4.01953125,
            "text": "Indian Muntjac, a Placental",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -4.08203125,
            "text": "Indian Muntjac, a Placental Mammal with Only Three Chromosomes.",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -4.7890625,
            "text": "Indian Muntjac, a Placental Mammal with Only Three Chromosomes",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -4.8359375,
            "text": "Indian Muntja",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -4.8515625,
            "text": "Indian",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -5.42578125,
            "text": "Indian Muntjac, a",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -5.5859375,
            "text": "Indian Mun",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -5.77734375,
            "text": "Indian Munt",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": 16.375,
            "text": "jac",
            "probability": 0.0
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 16.375,
            "text": "Muntjac",
            "probability": 0.0
        },
        {
            "start_logit": -7.53125,
            "end_logit": 16.375,
            "text": "tjac",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -8.140625,
            "text": "Indian Muntjac, a Placental Mammal with",
            "probability": 0.0
        },
        {
            "start_logit": 15.5859375,
            "end_logit": -8.6640625,
            "text": "Indian Muntjac, a Placental Mammal with Only",
            "probability": 0.0
        },
        {
            "start_logit": -1.6865234375,
            "end_logit": -1.4814453125,
            "text": "Placental Mammal with Only Three",
            "probability": 0.0
        },
        {
            "start_logit": -1.6865234375,
            "end_logit": -3.376953125,
            "text": "Placental Mammal",
            "probability": 0.0
        }
    ],
    "642c82c557b1c7a315000012_2": [
        {
            "start_logit": 15.4140625,
            "end_logit": 16.03125,
            "text": "Indian muntjac",
            "probability": 1.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -1.2421875,
            "text": "Indian muntjac, a placental mammal with the lowest known chromosome number (n = 3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -2.216796875,
            "text": "Indian muntjac, a placental mammal with the lowest known chromosome number (n",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -2.95703125,
            "text": "Indian muntjac,",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -3.44140625,
            "text": "Indian muntjac, a placental mammal with the lowest known chromosome number (n = 3).",
            "probability": 0.0
        },
        {
            "start_logit": -4.88671875,
            "end_logit": 16.03125,
            "text": "c",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -4.41796875,
            "text": "Indian muntjac, a placental mammal",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -4.44140625,
            "text": "Indian muntjac, a placental",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -5.09375,
            "text": "Indian muntja",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -5.09765625,
            "text": "Indian",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -5.19140625,
            "text": "Indian muntjac, a placental mammal with the lowest known chromosome number (n =",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -5.36328125,
            "text": "Indian munt",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -5.4296875,
            "text": "Indian mun",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -5.87109375,
            "text": "Indian muntjac, a",
            "probability": 0.0
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 16.03125,
            "text": "muntjac",
            "probability": 0.0
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 16.03125,
            "text": "jac",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -6.63671875,
            "text": "Indian muntjac, a placental mammal with the lowest known chromosome number (n = 3)",
            "probability": 0.0
        },
        {
            "start_logit": -7.671875,
            "end_logit": 16.03125,
            "text": "tjac",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -8.984375,
            "text": "Indian muntjac, a placental mammal with the lowest known chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 15.4140625,
            "end_logit": -9.2578125,
            "text": "Indian muntjac, a placental mammal with the lowest known chromosome number (",
            "probability": 0.0
        }
    ],
    "643305b257b1c7a315000025_0": [
        {
            "start_logit": 14.71875,
            "end_logit": 11.296875,
            "text": "Pharming",
            "probability": 1.0
        },
        {
            "start_logit": 14.71875,
            "end_logit": -5.08203125,
            "text": "Pharm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.71875,
            "end_logit": -9.328125,
            "text": "Pharming) is a new drug developed for the relief of symptoms occurring in patients with angioedema",
            "probability": 0.0
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 11.296875,
            "text": "Recombinant human C1 esterase inhibitor (rhC1INH) (Ruconest(\u00ae), Pharming",
            "probability": 0.0
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 11.296875,
            "text": ", Pharming",
            "probability": 0.0
        },
        {
            "start_logit": 14.71875,
            "end_logit": -10.5546875,
            "text": "Pharming) is a new drug",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 11.296875,
            "text": "C1 esterase inhibitor (rhC1INH) (Ruconest(\u00ae), Pharming",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 11.296875,
            "text": "H) (Ruconest(\u00ae), Pharming",
            "probability": 0.0
        },
        {
            "start_logit": 14.71875,
            "end_logit": -11.015625,
            "text": "Pharming) is a new drug developed for the relief of symptoms occurring in patients with angioedema due to C1-inhibitor deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 11.296875,
            "text": "ing",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 11.296875,
            "text": "inhibitor (rhC1INH) (Ruconest(\u00ae), Pharming",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 11.296875,
            "text": "esterase inhibitor (rhC1INH) (Ruconest(\u00ae), Pharming",
            "probability": 0.0
        },
        {
            "start_logit": -8.515625,
            "end_logit": 11.296875,
            "text": ") (Ruconest(\u00ae), Pharming",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 11.296875,
            "text": "human C1 esterase inhibitor (rhC1INH) (Ruconest(\u00ae), Pharming",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 11.296875,
            "text": "rhC1INH) (Ruconest(\u00ae), Pharming",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 11.296875,
            "text": "(Ruconest(\u00ae), Pharming",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 11.296875,
            "text": "Ruconest(\u00ae), Pharming",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": 11.296875,
            "text": "), Pharming",
            "probability": 0.0
        },
        {
            "start_logit": -6.41796875,
            "end_logit": -5.0078125,
            "text": "Recombinant human C1 esterase inhibitor (rhC1INH",
            "probability": 0.0
        },
        {
            "start_logit": -6.41796875,
            "end_logit": -5.08203125,
            "text": "Recombinant human C1 esterase inhibitor (rhC1INH) (Ruconest(\u00ae), Pharm",
            "probability": 0.0
        }
    ],
    "641635fa690f196b5100001c_0": [
        {
            "start_logit": -0.53076171875,
            "end_logit": 2.94921875,
            "text": "years",
            "probability": 1.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 2.94921875,
            "text": "ages in years",
            "probability": 0.00013875961303710938
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 2.94921875,
            "text": "The mean [median] ages in years",
            "probability": 4.035234451293945e-05
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 2.94921875,
            "text": "] ages in years",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": -0.53076171875,
            "end_logit": -9.90625,
            "text": "years of diagnostic milestones",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -0.53076171875,
            "end_logit": -10.3125,
            "text": "years of diagnostic milestones were: first signs, 2.7 [2.0]; first creatine kinase",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -0.53076171875,
            "end_logit": -10.7578125,
            "text": "years of diagnostic milestones were: first signs, 2.7 [2.0]; first creatine kinase (CK",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -0.53076171875,
            "end_logit": -11.4140625,
            "text": "years of diagnostic milestones were",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -0.53076171875,
            "end_logit": -11.5234375,
            "text": "years of",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -0.53076171875,
            "end_logit": -11.625,
            "text": "years of diagnostic milestones were: first signs, 2.7 [2.0]; first creatine kinase (CK), 4",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -9.90625,
            "text": "ages in years of diagnostic milestones",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -10.796875,
            "text": "muscle biopsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -10.3125,
            "text": "ages in years of diagnostic milestones were: first signs, 2.7 [2.0]; first creatine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -10.9921875,
            "text": "muscle",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -11.234375,
            "text": "muscle biopsy testing, 4.9 [4.8]; and time from first signs to diagnostic confirmation, 2",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -11.25,
            "text": "muscle biopsy testing, 4.9 [4.8]; and time from first signs to diagnostic confirmation, 2.2 [1",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -10.7578125,
            "text": "ages in years of diagnostic milestones were: first signs, 2.7 [2.0]; first creatine kinase (CK",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -11.3671875,
            "text": "muscle biopsy testing, 4.9 [4.8]; and time from first signs to diagnostic confirmation, 2.",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -11.5703125,
            "text": "muscle biopsy testing",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -11.6640625,
            "text": "muscle biopsy testing, 4.9 [4.8]; and time from first signs to diagnostic confirmation, 2.2 [1.4",
            "probability": 0.0
        }
    ],
    "641635fa690f196b5100001c_1": [
        {
            "start_logit": 10.8046875,
            "end_logit": 15.75,
            "text": "43 years",
            "probability": 0.9990234375
        },
        {
            "start_logit": 3.57421875,
            "end_logit": 15.75,
            "text": "4.43 years",
            "probability": 0.000720977783203125
        },
        {
            "start_logit": -2.701171875,
            "end_logit": 15.75,
            "text": ".43 years",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -4.5859375,
            "end_logit": 15.75,
            "text": "years",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.8828125,
            "end_logit": 15.75,
            "text": "The mean age of diagnosis was 4.43 years",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 15.75,
            "text": "age of diagnosis was 4.43 years",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": 15.75,
            "text": "mean age of diagnosis was 4.43 years",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 15.75,
            "text": "of diagnosis was 4.43 years",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 15.75,
            "text": "diagnosis was 4.43 years",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 15.75,
            "text": "was 4.43 years",
            "probability": 0.0
        },
        {
            "start_logit": 3.57421875,
            "end_logit": 1.0625,
            "text": "4",
            "probability": 0.0
        },
        {
            "start_logit": 10.8046875,
            "end_logit": -6.21875,
            "text": "43",
            "probability": 0.0
        },
        {
            "start_logit": 10.8046875,
            "end_logit": -8.296875,
            "text": "43 years.",
            "probability": 0.0
        },
        {
            "start_logit": 3.57421875,
            "end_logit": -1.2158203125,
            "text": "4.",
            "probability": 0.0
        },
        {
            "start_logit": 3.57421875,
            "end_logit": -6.21875,
            "text": "4.43",
            "probability": 0.0
        },
        {
            "start_logit": -4.8828125,
            "end_logit": 1.0625,
            "text": "The mean age of diagnosis was 4",
            "probability": 0.0
        },
        {
            "start_logit": -2.701171875,
            "end_logit": -1.2158203125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": 3.57421875,
            "end_logit": -8.296875,
            "text": "4.43 years.",
            "probability": 0.0
        },
        {
            "start_logit": -4.8828125,
            "end_logit": -1.2158203125,
            "text": "The mean age of diagnosis was 4.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 1.0625,
            "text": "age of diagnosis was 4",
            "probability": 0.0
        }
    ],
    "641635fa690f196b5100001c_2": [
        {
            "start_logit": 6.62109375,
            "end_logit": 15.3515625,
            "text": "9 years",
            "probability": 0.5810546875
        },
        {
            "start_logit": 6.29296875,
            "end_logit": 15.3515625,
            "text": "4.9 years",
            "probability": 0.41845703125
        },
        {
            "start_logit": -4.37109375,
            "end_logit": 15.3515625,
            "text": "The mean age for DMD diagnosis was 4.9 years",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -4.4453125,
            "end_logit": 15.3515625,
            "text": ".9 years",
            "probability": 9.119510650634766e-06
        },
        {
            "start_logit": -5.43359375,
            "end_logit": 15.3515625,
            "text": "years",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": -5.62109375,
            "end_logit": 15.3515625,
            "text": "DMD diagnosis was 4.9 years",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 15.3515625,
            "text": "age for DMD diagnosis was 4.9 years",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 15.3515625,
            "text": "mean age for DMD diagnosis was 4.9 years",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.765625,
            "end_logit": 15.3515625,
            "text": "for DMD diagnosis was 4.9 years",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.29296875,
            "end_logit": -0.77294921875,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 15.3515625,
            "text": "was 4.9 years",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 15.3515625,
            "text": "diagnosis was 4.9 years",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.29296875,
            "end_logit": -3.158203125,
            "text": "4.",
            "probability": 0.0
        },
        {
            "start_logit": 6.62109375,
            "end_logit": -8.0390625,
            "text": "9 years.",
            "probability": 0.0
        },
        {
            "start_logit": 6.29296875,
            "end_logit": -8.0390625,
            "text": "4.9 years.",
            "probability": 0.0
        },
        {
            "start_logit": 6.62109375,
            "end_logit": -8.734375,
            "text": "9",
            "probability": 0.0
        },
        {
            "start_logit": 6.29296875,
            "end_logit": -8.734375,
            "text": "4.9",
            "probability": 0.0
        },
        {
            "start_logit": -4.37109375,
            "end_logit": -0.77294921875,
            "text": "The mean age for DMD diagnosis was 4",
            "probability": 0.0
        },
        {
            "start_logit": -5.62109375,
            "end_logit": -0.77294921875,
            "text": "DMD diagnosis was 4",
            "probability": 0.0
        },
        {
            "start_logit": -4.37109375,
            "end_logit": -3.158203125,
            "text": "The mean age for DMD diagnosis was 4.",
            "probability": 0.0
        }
    ],
    "641635fa690f196b5100001c_3": [
        {
            "start_logit": 8.7578125,
            "end_logit": 12.3828125,
            "text": "3 and 11 years of age",
            "probability": 0.9853515625
        },
        {
            "start_logit": 4.515625,
            "end_logit": 12.3828125,
            "text": "11 years of age",
            "probability": 0.0142822265625
        },
        {
            "start_logit": 8.7578125,
            "end_logit": 1.3447265625,
            "text": "3 and 11 years",
            "probability": 1.5795230865478516e-05
        },
        {
            "start_logit": -2.3203125,
            "end_logit": 12.3828125,
            "text": "between 3 and 11 years of age",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -4.15234375,
            "end_logit": 12.3828125,
            "text": "of age",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -4.49609375,
            "end_logit": 12.3828125,
            "text": "age",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -4.6015625,
            "end_logit": 12.3828125,
            "text": "years of age",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 4.515625,
            "end_logit": 1.3447265625,
            "text": "11 years",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -3.359375,
            "text": "3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 12.3828125,
            "text": "and 11 years of age",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.421875,
            "end_logit": 12.3828125,
            "text": "locomotion problems (45.4%) the diagnosis was made between 3 and 11 years of age",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -4.921875,
            "text": "3 and 11",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.21875,
            "end_logit": 12.3828125,
            "text": "the diagnosis was made between 3 and 11 years of age",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 12.3828125,
            "text": "In 10 cases of the group with locomotion problems (45.4%) the diagnosis was made between 3 and 11 years of age",
            "probability": 0.0
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -5.94140625,
            "text": "3 and",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 12.3828125,
            "text": "45.4%) the diagnosis was made between 3 and 11 years of age",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 12.3828125,
            "text": "diagnosis was made between 3 and 11 years of age",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 12.3828125,
            "text": "10 cases of the group with locomotion problems (45.4%) the diagnosis was made between 3 and 11 years of age",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 12.3828125,
            "text": "the group with locomotion problems (45.4%) the diagnosis was made between 3 and 11 years of age",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 12.3828125,
            "text": "4%) the diagnosis was made between 3 and 11 years of age",
            "probability": 0.0
        }
    ],
    "6433050157b1c7a315000024_0": [
        {
            "start_logit": 14.1796875,
            "end_logit": 13.390625,
            "text": "Conestat alfa",
            "probability": 1.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -2.564453125,
            "text": "Conestat",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -5.125,
            "text": "Conestat alfa (Ruconest, rhC1INH)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -6.1015625,
            "text": "Cones",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -6.265625,
            "text": "Conesta",
            "probability": 0.0
        },
        {
            "start_logit": -5.5703125,
            "end_logit": 13.390625,
            "text": "alfa",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -7.15625,
            "text": "Conestat alfa (",
            "probability": 0.0
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 13.390625,
            "text": "t alfa",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -7.72265625,
            "text": "Conestat alfa (Ruconest",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 13.390625,
            "text": "tat alfa",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -9.1015625,
            "text": "Conestat alfa (Ruconest, rh",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -9.375,
            "text": "Conestat alfa (Ruconest, rhC1INH",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -9.7890625,
            "text": "Conestat alfa (Ruconest, rhC1INH) is the",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -10.25,
            "text": "Conestat alfa (Ruconest,",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -10.2890625,
            "text": "Conestat alfa (Ruconest, rhC1INH) is the first",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -10.4375,
            "text": "Conestat alfa (Ruconest, rhC1INH) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -10.53125,
            "text": "Conestat alfa (Ru",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -10.7421875,
            "text": "Conestat alfa (Ruconest, rhC1",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -11.1796875,
            "text": "Conestat alfa (Rucon",
            "probability": 0.0
        },
        {
            "start_logit": -6.62890625,
            "end_logit": -2.564453125,
            "text": "t",
            "probability": 0.0
        }
    ],
    "6417900b690f196b5100002a_0": [
        {
            "start_logit": 12.7109375,
            "end_logit": 9.8125,
            "text": "Duchenne muscular dystrophy",
            "probability": 1.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -5.30078125,
            "text": "Duchenne muscular dystrophy (DMD",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -6.1875,
            "text": "Duchenne",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -6.65234375,
            "text": "Duchenne muscular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -6.99609375,
            "text": "Duchenne muscular dystrophy (DMD)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.234375,
            "end_logit": 9.8125,
            "text": "dystrophy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.78125,
            "end_logit": 9.8125,
            "text": "muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 9.8125,
            "text": "of Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -6.9375,
            "end_logit": 9.8125,
            "text": "DMD gene for the treatment of Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.8125,
            "text": "treatment of Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.8125,
            "text": "the treatment of Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -11.125,
            "text": "Duchenne muscular dystrophy (",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 9.8125,
            "text": "skip exon 53 of the DMD gene for the treatment of Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 9.8125,
            "text": "the DMD gene for the treatment of Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 9.8125,
            "text": "odiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene for the treatment of Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 9.8125,
            "text": "PMO) designed to skip exon 53 of the DMD gene for the treatment of Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 9.8125,
            "text": "te morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene for the treatment of Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -4.234375,
            "end_logit": -5.30078125,
            "text": "dystrophy (DMD",
            "probability": 0.0
        },
        {
            "start_logit": -5.78125,
            "end_logit": -5.30078125,
            "text": "muscular dystrophy (DMD",
            "probability": 0.0
        },
        {
            "start_logit": -5.8828125,
            "end_logit": -5.30078125,
            "text": "of Duchenne muscular dystrophy (DMD",
            "probability": 0.0
        }
    ],
    "6417900b690f196b5100002a_1": [
        {
            "start_logit": 9.4765625,
            "end_logit": 7.1015625,
            "text": "dystrophin",
            "probability": 0.93359375
        },
        {
            "start_logit": 2.337890625,
            "end_logit": 11.265625,
            "text": "DMD gene by skipping  exon 53",
            "probability": 0.047576904296875
        },
        {
            "start_logit": 1.345703125,
            "end_logit": 11.265625,
            "text": "skipping  exon 53",
            "probability": 0.01763916015625
        },
        {
            "start_logit": 2.337890625,
            "end_logit": 7.1015625,
            "text": "DMD gene by skipping  exon 53 and produces a truncated but functional form of dystrophin",
            "probability": 0.0007390975952148438
        },
        {
            "start_logit": 1.345703125,
            "end_logit": 7.1015625,
            "text": "skipping  exon 53 and produces a truncated but functional form of dystrophin",
            "probability": 0.0002741813659667969
        },
        {
            "start_logit": -5.04296875,
            "end_logit": 11.265625,
            "text": "Viltolarsen restores the reading frame of the DMD gene by skipping  exon 53",
            "probability": 2.962350845336914e-05
        },
        {
            "start_logit": -5.265625,
            "end_logit": 11.265625,
            "text": "53",
            "probability": 2.378225326538086e-05
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -5.484375,
            "text": "dystrophin.",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 2.337890625,
            "end_logit": 1.2353515625,
            "text": "DMD",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 11.265625,
            "text": "ipping  exon 53",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -8.328125,
            "end_logit": 11.265625,
            "text": "exon 53",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -8.484375,
            "end_logit": 11.265625,
            "text": "olarsen restores the reading frame of the DMD gene by skipping  exon 53",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -8.796875,
            "end_logit": 11.265625,
            "text": "ltolarsen restores the reading frame of the DMD gene by skipping  exon 53",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -8.8125,
            "end_logit": 11.265625,
            "text": "the DMD gene by skipping  exon 53",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.04296875,
            "end_logit": 7.1015625,
            "text": "Viltolarsen restores the reading frame of the DMD gene by skipping  exon 53 and produces a truncated but functional form of dystrophin",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 11.265625,
            "text": "restores the reading frame of the DMD gene by skipping  exon 53",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.265625,
            "end_logit": 7.1015625,
            "text": "53 and produces a truncated but functional form of dystrophin",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -9.546875,
            "end_logit": 11.265625,
            "text": "en restores the reading frame of the DMD gene by skipping  exon 53",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 11.265625,
            "text": "by skipping  exon 53",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 7.1015625,
            "text": "ipping  exon 53 and produces a truncated but functional form of dystrophin",
            "probability": 0.0
        }
    ],
    "64178fea690f196b51000028_0": [
        {
            "start_logit": 14.65625,
            "end_logit": 13.5078125,
            "text": "Duchenne muscular dystrophy",
            "probability": 1.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -5.375,
            "text": "Duchenne",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -6.38671875,
            "text": "Duchenne muscular",
            "probability": 0.0
        },
        {
            "start_logit": -5.57421875,
            "end_logit": 13.5078125,
            "text": "dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -6.2109375,
            "end_logit": 13.5078125,
            "text": "muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.359375,
            "text": "Duchenne muscular dystrophy and",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.796875,
            "text": "Duchenne muscular dystrophy and confirmed exon-51 amenable genetic mutations",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -10.1484375,
            "text": "Duchenne muscular dystrophy and confirmed exon-51",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -10.3984375,
            "text": "Duchenne muscular dystrophy and confirmed exon-51 amenable genetic mutations.",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": 13.5078125,
            "text": "with Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 13.5078125,
            "text": "treatment effects of eteplirsen over 4 years in patients with Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -11.2421875,
            "text": "Duchenne muscular dystrophy and confirmed",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -11.296875,
            "text": "Duchenne muscular dystrophy and confirmed exon-51 amenable",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 13.5078125,
            "text": "eteplirsen over 4 years in patients with Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -11.7734375,
            "text": "Duchenne muscular dystrophy and confirmed exon-51 amenable genetic",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 13.5078125,
            "text": "patients with Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 13.5078125,
            "text": "4 years in patients with Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 13.5078125,
            "text": "eplirsen over 4 years in patients with Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.5078125,
            "text": "en over 4 years in patients with Duchenne muscular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -6.2109375,
            "end_logit": -6.38671875,
            "text": "muscular",
            "probability": 0.0
        }
    ],
    "64178fea690f196b51000028_1": [
        {
            "start_logit": 11.984375,
            "end_logit": 7.04296875,
            "text": "dystrophin",
            "probability": 1.0
        },
        {
            "start_logit": 11.984375,
            "end_logit": -6.1171875,
            "text": "dystrophin production",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 11.984375,
            "end_logit": -6.16796875,
            "text": "dystrophin production in exon 51",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 11.984375,
            "end_logit": -8.984375,
            "text": "dystrophin production in exon 51-amenable",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.984375,
            "end_logit": -10.03125,
            "text": "dystrophin production in exon 51-amenable patients",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.984375,
            "end_logit": -10.8046875,
            "text": "dystrophin production in exon 51-",
            "probability": 0.0
        },
        {
            "start_logit": 11.984375,
            "end_logit": -11.0078125,
            "text": "dystrophin production in exon 51-amenable patients treated with eteplirsen (EXONDYS 51\u00ae)",
            "probability": 0.0
        },
        {
            "start_logit": 11.984375,
            "end_logit": -11.3125,
            "text": "dystrophin production in",
            "probability": 0.0
        },
        {
            "start_logit": 11.984375,
            "end_logit": -11.9296875,
            "text": "dystrophin production in exon 51-amenable patients treated with eteplirsen (EXONDYS 51",
            "probability": 0.0
        },
        {
            "start_logit": 11.984375,
            "end_logit": -12.015625,
            "text": "dystrophin production in exon 51-amenable patients treated",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 7.04296875,
            "text": "exon skipping and dystrophin",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 7.04296875,
            "text": "A relationship between exon skipping and dystrophin",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 7.04296875,
            "text": "skipping and dystrophin",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": -6.16796875,
            "text": "exon 51",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": -6.16796875,
            "text": "51",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": -6.1171875,
            "text": "production",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": -6.16796875,
            "text": "production in exon 51",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": -6.1171875,
            "text": "exon skipping and dystrophin production",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": -6.16796875,
            "text": "exon skipping and dystrophin production in exon 51",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -6.1171875,
            "text": "A relationship between exon skipping and dystrophin production",
            "probability": 0.0
        }
    ],
    "6426d131690f196b5100004e_0": [
        {
            "start_logit": 14.859375,
            "end_logit": 13.4453125,
            "text": "hepatic",
            "probability": 1.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -10.59375,
            "text": "hepatic uptake",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -10.6875,
            "text": "hepatic uptake mechanism, competing with the Ashwell-receptor-mediated internalization of galactose-terminated glycoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -10.90625,
            "text": "hepatic uptake mechanism, competing with the Ashwell-receptor-mediated internalization of galactose",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -11.375,
            "text": "hepatic uptake mechanism, competing",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 13.4453125,
            "text": "From these data, we inferred an additional hepatic",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -11.4140625,
            "text": "hepatic uptake mechanism, competing with the Ashwell-receptor-mediated internalization",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -11.4296875,
            "text": "hepatic uptake mechanism, competing with the Ashwell-receptor-mediated internalization of",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -11.4765625,
            "text": "hepatic uptake mechanism",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -11.5,
            "text": "hepatic uptake mechanism, competing with the Ashwell-receptor-mediated internalization of galactose-",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -11.5390625,
            "text": "hepatic uptake mechanism, competing with the Ashwell-receptor-mediated internalization of galactose-terminated glycoproteins",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -11.6640625,
            "text": "hepatic uptake mechanism,",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 13.4453125,
            "text": "additional hepatic",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 13.4453125,
            "text": "we inferred an additional hepatic",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 13.4453125,
            "text": "these data, we inferred an additional hepatic",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 13.4453125,
            "text": ", we inferred an additional hepatic",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 13.4453125,
            "text": "inferred an additional hepatic",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -11.8359375,
            "text": "hepatic uptake mechanism, competing with the Ashwell-receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -11.96875,
            "text": "hepatic uptake mechanism, competing with the Ashwell-",
            "probability": 0.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -12.0078125,
            "text": "hepatic uptake mechanism, competing with the",
            "probability": 0.0
        }
    ],
    "6426d131690f196b5100004e_1": [
        {
            "start_logit": 14.0,
            "end_logit": 14.25,
            "text": "hepatocyte",
            "probability": 1.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": 14.25,
            "text": "the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 14.25,
            "text": "albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 14.25,
            "text": "binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 14.25,
            "text": "osylated albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 14.25,
            "text": "both models, using lactosylated albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 14.25,
            "text": "designed to investigate several aspects of both models, using lactosylated albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 14.25,
            "text": "the Ashwell receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 14.25,
            "text": "lactosylated albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 14.25,
            "text": "on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 14.25,
            "text": "present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 14.25,
            "text": "Ashwell receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 14.25,
            "text": "using lactosylated albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 14.25,
            "text": "to investigate several aspects of both models, using lactosylated albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.25,
            "text": "well receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 14.25,
            "text": "a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -10.6015625,
            "text": "hepatocyte.",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": -9.84375,
            "text": "the",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": -10.6015625,
            "text": "the hepatocyte.",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": -9.84375,
            "text": "albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the",
            "probability": 0.0
        }
    ],
    "6426d131690f196b5100004e_2": [
        {
            "start_logit": 14.796875,
            "end_logit": 13.5234375,
            "text": "hepatic",
            "probability": 1.0
        },
        {
            "start_logit": -5.625,
            "end_logit": 13.5234375,
            "text": "The asialoglycoprotein receptor (ASGPR) is a hepatic",
            "probability": 0.0
        },
        {
            "start_logit": 14.796875,
            "end_logit": -8.7578125,
            "text": "hepatic receptor that mediates removal of potentially hazardous glycoconjugates from blood in health and disease. T",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 13.5234375,
            "text": "asialoglycoprotein receptor (ASGPR) is a hepatic",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 13.5234375,
            "text": "a hepatic",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 13.5234375,
            "text": "oprotein receptor (ASGPR) is a hepatic",
            "probability": 0.0
        },
        {
            "start_logit": 14.796875,
            "end_logit": -10.859375,
            "text": "hepatic receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.59375,
            "end_logit": 13.5234375,
            "text": "receptor (ASGPR) is a hepatic",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 13.5234375,
            "text": "loglycoprotein receptor (ASGPR) is a hepatic",
            "probability": 0.0
        },
        {
            "start_logit": 14.796875,
            "end_logit": -10.921875,
            "text": "hepatic receptor that mediates removal",
            "probability": 0.0
        },
        {
            "start_logit": 14.796875,
            "end_logit": -10.9296875,
            "text": "hepatic receptor that mediates removal of",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 13.5234375,
            "text": "glycoprotein receptor (ASGPR) is a hepatic",
            "probability": 0.0
        },
        {
            "start_logit": 14.796875,
            "end_logit": -11.0703125,
            "text": "hepatic receptor that mediates removal of potentially hazardous glycoconjugates from blood in health and disease.",
            "probability": 0.0
        },
        {
            "start_logit": 14.796875,
            "end_logit": -11.1171875,
            "text": "hepatic receptor that",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 13.5234375,
            "text": "GPR) is a hepatic",
            "probability": 0.0
        },
        {
            "start_logit": 14.796875,
            "end_logit": -11.2578125,
            "text": "hepatic receptor that mediates removal of potentially hazardous glycoconjugates from blood",
            "probability": 0.0
        },
        {
            "start_logit": 14.796875,
            "end_logit": -11.3984375,
            "text": "hepatic receptor that mediates",
            "probability": 0.0
        },
        {
            "start_logit": -5.625,
            "end_logit": -9.046875,
            "text": "The",
            "probability": 0.0
        },
        {
            "start_logit": -6.4765625,
            "end_logit": -8.7578125,
            "text": "T",
            "probability": 0.0
        },
        {
            "start_logit": -5.625,
            "end_logit": -9.6640625,
            "text": "The asialoglycoprotein receptor",
            "probability": 0.0
        }
    ],
    "6426d131690f196b5100004e_3": [
        {
            "start_logit": 14.78125,
            "end_logit": 13.5078125,
            "text": "hepatocytes",
            "probability": 1.0
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 13.5078125,
            "text": "The Ashwell receptor, the major lectin of hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 13.5078125,
            "text": "lectin of hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 13.5078125,
            "text": "major lectin of hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 13.5078125,
            "text": "of hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -8.46875,
            "end_logit": 13.5078125,
            "text": "Ashwell receptor, the major lectin of hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 13.5078125,
            "text": "the major lectin of hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -10.6171875,
            "text": "hepatocytes,",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 13.5078125,
            "text": "receptor, the major lectin of hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 13.5078125,
            "text": ", the major lectin of hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 13.5078125,
            "text": "well receptor, the major lectin of hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -11.46875,
            "text": "hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -11.734375,
            "text": "hepatocytes, rapidly clear",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -11.8515625,
            "text": "hepatocytes, rapidly clears",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -11.9296875,
            "text": "hepatocytes, rapidly clears from blood circulation",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -12.015625,
            "text": "hepatocytes, rapidly",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -12.1484375,
            "text": "hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose",
            "probability": 0.0
        },
        {
            "start_logit": -6.88671875,
            "end_logit": -7.48828125,
            "text": "The Ashwell receptor, the major lectin of",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -7.48828125,
            "text": "lectin of",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -7.48828125,
            "text": "major lectin of",
            "probability": 0.0
        }
    ],
    "64178ffb690f196b51000029_0": [
        {
            "start_logit": 13.1484375,
            "end_logit": 11.6640625,
            "text": "DMD",
            "probability": 1.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -7.57421875,
            "text": "DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -8.140625,
            "text": "DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -8.453125,
            "text": "DMD in patients who have a confirmed mutation of the DMD",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -9.3984375,
            "text": "DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 sk",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 11.6640625,
            "text": "treatment of DMD",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 11.6640625,
            "text": "Casimersen received its first approval on 25 February 2021, in the USA, for the treatment of DMD",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": 11.6640625,
            "text": "the treatment of DMD",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -10.6640625,
            "text": "DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -10.953125,
            "text": "DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 11.6640625,
            "text": "of DMD",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -11.5546875,
            "text": "DMD in patients who have a confirmed mutation of the DMD gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 11.6640625,
            "text": "approval on 25 February 2021, in the USA, for the treatment of DMD",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -11.90625,
            "text": "DMD in patients who have a confirmed mutation of the DMD gene that",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 11.6640625,
            "text": "imersen received its first approval on 25 February 2021, in the USA, for the treatment of DMD",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -12.0390625,
            "text": "DMD in patients who",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -12.0625,
            "text": "DMD in patients who have a confirmed mutation of the DMD gene that is amenable to",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -12.1640625,
            "text": "DMD in",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 11.6640625,
            "text": "USA, for the treatment of DMD",
            "probability": 0.0
        },
        {
            "start_logit": -6.76953125,
            "end_logit": -7.57421875,
            "text": "DMD gene that is amenable to exon 45 skipping",
            "probability": 0.0
        }
    ],
    "63eeefc5f36125a426000009_0": [
        {
            "start_logit": 8.015625,
            "end_logit": 8.6328125,
            "text": "Plasmodium falciparum",
            "probability": 1.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": 8.6328125,
            "text": "BACKGROUND: CIS43LS is a monoclonal antibody that was shown to protect against controlled Plasmodium falciparum",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.6328125,
            "text": "falciparum",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 8.6328125,
            "text": "CIS43LS is a monoclonal antibody that was shown to protect against controlled Plasmodium falciparum",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.6328125,
            "text": "protect against controlled Plasmodium falciparum",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.015625,
            "end_logit": -8.703125,
            "text": "Plasmodium",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 8.6328125,
            "text": "a monoclonal antibody that was shown to protect against controlled Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 8.015625,
            "end_logit": -10.0390625,
            "text": "Plasmodium falciparum infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 8.6328125,
            "text": "antibody that was shown to protect against controlled Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 8.6328125,
            "text": "monoclonal antibody that was shown to protect against controlled Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 8.015625,
            "end_logit": -10.3046875,
            "text": "Plasmodium falciparum infection in a phase 1 clinical trial.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 8.6328125,
            "text": ": CIS43LS is a monoclonal antibody that was shown to protect against controlled Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.2109375,
            "end_logit": 8.6328125,
            "text": "against controlled Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.359375,
            "end_logit": 8.6328125,
            "text": "43LS is a monoclonal antibody that was shown to protect against controlled Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.3984375,
            "end_logit": 8.6328125,
            "text": "controlled Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.40625,
            "end_logit": 8.6328125,
            "text": "shown to protect against controlled Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.5078125,
            "end_logit": 8.6328125,
            "text": "to protect against controlled Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.5703125,
            "end_logit": 8.6328125,
            "text": "that was shown to protect against controlled Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.5703125,
            "end_logit": 8.6328125,
            "text": "was shown to protect against controlled Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 8.015625,
            "end_logit": -11.28125,
            "text": "Plasmodium falciparum infection in a",
            "probability": 0.0
        }
    ],
    "63eeefc5f36125a426000009_1": [
        {
            "start_logit": 10.40625,
            "end_logit": 12.15625,
            "text": "P. falciparum",
            "probability": 1.0
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 12.15625,
            "text": "falciparum",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.40625,
            "end_logit": -6.33203125,
            "text": "P. falciparum infection in healthy adults in Mali over a 6-month malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.40625,
            "end_logit": -7.1015625,
            "text": "P",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 12.15625,
            "text": "against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 10.40625,
            "end_logit": -9.1328125,
            "text": "P. falciparum infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 12.15625,
            "text": "METHODS: We conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 12.15625,
            "text": "safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 12.15625,
            "text": "a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 12.15625,
            "text": "efficacy of a single intravenous infusion of CIS43LS against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.09375,
            "end_logit": 12.15625,
            "text": "conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 12.15625,
            "text": "phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 12.15625,
            "text": "trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.1328125,
            "end_logit": 12.15625,
            "text": "the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.2421875,
            "end_logit": 12.15625,
            "text": "CIS43LS against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.2734375,
            "end_logit": 12.15625,
            "text": "43LS against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -11.3203125,
            "end_logit": 12.15625,
            "text": "2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 10.40625,
            "end_logit": -10.71875,
            "text": "P.",
            "probability": 0.0
        },
        {
            "start_logit": 10.40625,
            "end_logit": -11.0,
            "text": "P. falciparum infection in healthy adults in Mali over a 6-month malaria season.",
            "probability": 0.0
        },
        {
            "start_logit": 10.40625,
            "end_logit": -11.0546875,
            "text": "P. falciparum infection in healthy adults in Mali over a 6-month malaria season",
            "probability": 0.0
        }
    ],
    "63eeefc5f36125a426000009_2": [
        {
            "start_logit": 11.84375,
            "end_logit": 13.75,
            "text": "P. falciparum",
            "probability": 1.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -3.37890625,
            "text": "P. falciparum infection over a 6-month malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.9453125,
            "end_logit": 13.75,
            "text": "falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 13.75,
            "text": ". falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -6.29296875,
            "text": "P.",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": 13.75,
            "text": "protective against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -7.1015625,
            "text": "P",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 13.75,
            "text": "CIS43LS was protective against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -7.6640625,
            "text": "P. falciparum infection over a 6-month malaria season",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -8.4609375,
            "text": "P. falciparum infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 13.75,
            "text": "against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 13.75,
            "text": "CONCLUSIONS: CIS43LS was protective against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 13.75,
            "text": "43LS was protective against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 13.75,
            "text": "was protective against P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -9.234375,
            "text": "P. falciparum infection over a 6-month malaria season in Mali without evident safety concerns.",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -10.5546875,
            "text": "P. falciparum infection over a 6-month malaria season in",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -10.9765625,
            "text": "P. falciparum infection over a 6-month malaria season in Mali",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -11.09375,
            "text": "P. falciparum infection over a 6-month malaria season in Mal",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -11.1015625,
            "text": "P. falciparum infection over a",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -11.234375,
            "text": "P. falciparum infection over",
            "probability": 0.0
        }
    ],
    "63eeefc5f36125a426000009_3": [
        {
            "start_logit": 2.05078125,
            "end_logit": 0.1519775390625,
            "text": "malaria",
            "probability": 0.9951171875
        },
        {
            "start_logit": 2.05078125,
            "end_logit": -5.18359375,
            "text": "malaria prevention.",
            "probability": 0.004791259765625
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 0.1519775390625,
            "text": "Based on these data, CIS43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria",
            "probability": 0.00011807680130004883
        },
        {
            "start_logit": 2.05078125,
            "end_logit": -10.7890625,
            "text": "malaria prevention",
            "probability": 1.7702579498291016e-05
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 0.1519775390625,
            "text": "CIS43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 0.1519775390625,
            "text": "AAV delivery provides a potential next-generation approach for malaria",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 0.1519775390625,
            "text": "advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 0.1519775390625,
            "text": "potential next-generation approach for malaria",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -10.640625,
            "end_logit": 0.1519775390625,
            "text": "these data, CIS43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 0.1519775390625,
            "text": "approach for malaria",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 0.1519775390625,
            "text": ", CIS43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 0.1519775390625,
            "text": "43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 0.1519775390625,
            "text": "on these data, CIS43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -10.96875,
            "end_logit": 0.1519775390625,
            "text": "data, CIS43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 0.1519775390625,
            "text": "generation approach for malaria",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -11.0625,
            "end_logit": 0.1519775390625,
            "text": "phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 0.1519775390625,
            "text": "next-generation approach for malaria",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -11.125,
            "end_logit": 0.1519775390625,
            "text": "a potential next-generation approach for malaria",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -11.1328125,
            "end_logit": 0.1519775390625,
            "text": "for malaria",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 0.1519775390625,
            "text": "to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria",
            "probability": 1.7881393432617188e-06
        }
    ],
    "63eeefc5f36125a426000009_4": [
        {
            "start_logit": -0.75146484375,
            "end_logit": -3.560546875,
            "text": "Plasmodium falciparum",
            "probability": 0.994140625
        },
        {
            "start_logit": -0.75146484375,
            "end_logit": -9.359375,
            "text": "Plasmodium",
            "probability": 0.0030193328857421875
        },
        {
            "start_logit": -0.75146484375,
            "end_logit": -9.6875,
            "text": "Plasmodium falciparum.",
            "probability": 0.00217437744140625
        },
        {
            "start_logit": -10.421875,
            "end_logit": -3.560546875,
            "text": "falciparum",
            "probability": 6.264448165893555e-05
        },
        {
            "start_logit": -10.734375,
            "end_logit": -3.560546875,
            "text": "antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum",
            "probability": 4.583597183227539e-05
        },
        {
            "start_logit": -10.8125,
            "end_logit": -3.560546875,
            "text": "antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum",
            "probability": 4.2438507080078125e-05
        },
        {
            "start_logit": -10.9375,
            "end_logit": -3.560546875,
            "text": "the safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum",
            "probability": 3.737211227416992e-05
        },
        {
            "start_logit": -11.0,
            "end_logit": -3.560546875,
            "text": "infection with Plasmodium falciparum",
            "probability": 3.516674041748047e-05
        },
        {
            "start_logit": -11.0078125,
            "end_logit": -3.560546875,
            "text": "safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum",
            "probability": 3.4928321838378906e-05
        },
        {
            "start_logit": -11.2578125,
            "end_logit": -3.560546875,
            "text": "efficacy against infection with Plasmodium falciparum",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": -11.328125,
            "end_logit": -3.560546875,
            "text": "extended half-life, and its efficacy against infection with Plasmodium falciparum",
            "probability": 2.5331974029541016e-05
        },
        {
            "start_logit": -11.40625,
            "end_logit": -3.560546875,
            "text": "CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum",
            "probability": 2.3424625396728516e-05
        },
        {
            "start_logit": -11.4140625,
            "end_logit": -3.560546875,
            "text": "monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum",
            "probability": 2.3245811462402344e-05
        },
        {
            "start_logit": -11.4609375,
            "end_logit": -3.560546875,
            "text": "half-life, and its efficacy against infection with Plasmodium falciparum",
            "probability": 2.2172927856445312e-05
        },
        {
            "start_logit": -10.734375,
            "end_logit": -9.359375,
            "text": "antibody with an extended half-life, and its efficacy against infection with Plasmodium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.421875,
            "end_logit": -9.6875,
            "text": "falciparum.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8125,
            "end_logit": -9.359375,
            "text": "antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.9375,
            "end_logit": -9.359375,
            "text": "the safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.0,
            "end_logit": -9.359375,
            "text": "infection with Plasmodium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.0078125,
            "end_logit": -9.359375,
            "text": "safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium",
            "probability": 1.1920928955078125e-07
        }
    ],
    "63eeefc5f36125a426000009_5": [
        {
            "start_logit": -1.814453125,
            "end_logit": -3.029296875,
            "text": "malaria",
            "probability": 0.9384765625
        },
        {
            "start_logit": -1.814453125,
            "end_logit": -5.796875,
            "text": "malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection.",
            "probability": 0.059051513671875
        },
        {
            "start_logit": -1.814453125,
            "end_logit": -10.4375,
            "text": "malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria",
            "probability": 0.0005702972412109375
        },
        {
            "start_logit": -1.814453125,
            "end_logit": -10.609375,
            "text": "malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented",
            "probability": 0.0004801750183105469
        },
        {
            "start_logit": -1.814453125,
            "end_logit": -11.3203125,
            "text": "malaria infection or vaccination,",
            "probability": 0.0002359151840209961
        },
        {
            "start_logit": -1.814453125,
            "end_logit": -11.375,
            "text": "malaria infection or vaccination",
            "probability": 0.0002231597900390625
        },
        {
            "start_logit": -1.814453125,
            "end_logit": -11.4765625,
            "text": "malaria infection or vaccination, administration of the long-",
            "probability": 0.00020170211791992188
        },
        {
            "start_logit": -1.814453125,
            "end_logit": -11.546875,
            "text": "malaria infection",
            "probability": 0.00018799304962158203
        },
        {
            "start_logit": -1.814453125,
            "end_logit": -11.6328125,
            "text": "malaria infection or vaccination, administration of the long-acting monoclonal antibody",
            "probability": 0.00017249584197998047
        },
        {
            "start_logit": -1.814453125,
            "end_logit": -11.65625,
            "text": "malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after",
            "probability": 0.0001685619354248047
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -3.029296875,
            "text": "Among adults who had never had malaria",
            "probability": 0.0001430511474609375
        },
        {
            "start_logit": -11.03125,
            "end_logit": -3.029296875,
            "text": "CONCLUSIONS: Among adults who had never had malaria",
            "probability": 9.310245513916016e-05
        },
        {
            "start_logit": -11.578125,
            "end_logit": -3.029296875,
            "text": "who had never had malaria",
            "probability": 5.3882598876953125e-05
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -5.796875,
            "text": "malaria after controlled infection.",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -5.796875,
            "text": "Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection.",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -5.796875,
            "text": "antibody CIS43LS prevented malaria after controlled infection.",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -11.0234375,
            "end_logit": -5.796875,
            "text": "acting monoclonal antibody CIS43LS prevented malaria after controlled infection.",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": -11.03125,
            "end_logit": -5.796875,
            "text": "CONCLUSIONS: Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection.",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": -11.0625,
            "end_logit": -5.796875,
            "text": "administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection.",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -11.125,
            "end_logit": -5.796875,
            "text": "controlled infection.",
            "probability": 5.304813385009766e-06
        }
    ],
    "64172bb2690f196b5100001e_0": [
        {
            "start_logit": 10.828125,
            "end_logit": 11.6484375,
            "text": "promoters",
            "probability": 1.0
        },
        {
            "start_logit": -5.53125,
            "end_logit": 11.6484375,
            "text": "RNA polymerases initiate transcription at DNA sequences called promoters",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 11.6484375,
            "text": "called promoters",
            "probability": 0.0
        },
        {
            "start_logit": 10.828125,
            "end_logit": -7.23046875,
            "text": "promoters.",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 11.6484375,
            "text": "at DNA sequences called promoters",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 11.6484375,
            "text": "DNA sequences called promoters",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 11.6484375,
            "text": "polymerases initiate transcription at DNA sequences called promoters",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.6484375,
            "text": "transcription at DNA sequences called promoters",
            "probability": 0.0
        },
        {
            "start_logit": -11.09375,
            "end_logit": 11.6484375,
            "text": "initiate transcription at DNA sequences called promoters",
            "probability": 0.0
        },
        {
            "start_logit": -11.1796875,
            "end_logit": 11.6484375,
            "text": "sequences called promoters",
            "probability": 0.0
        },
        {
            "start_logit": -5.53125,
            "end_logit": -7.23046875,
            "text": "RNA polymerases initiate transcription at DNA sequences called promoters.",
            "probability": 0.0
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -7.23046875,
            "text": "called promoters.",
            "probability": 0.0
        },
        {
            "start_logit": -5.53125,
            "end_logit": -10.6875,
            "text": "RNA polymerases initiate transcription at DNA sequences",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": -7.23046875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": -7.23046875,
            "text": "at DNA sequences called promoters.",
            "probability": 0.0
        },
        {
            "start_logit": -5.53125,
            "end_logit": -11.3515625,
            "text": "RNA polymerases initiate transcription at DNA sequences called",
            "probability": 0.0
        },
        {
            "start_logit": -5.53125,
            "end_logit": -11.46875,
            "text": "RNA polymerases initiate transcription at DNA",
            "probability": 0.0
        },
        {
            "start_logit": -5.53125,
            "end_logit": -11.5078125,
            "text": "RNA",
            "probability": 0.0
        },
        {
            "start_logit": -5.53125,
            "end_logit": -11.734375,
            "text": "RNA polymerases initiate",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -7.23046875,
            "text": "DNA sequences called promoters.",
            "probability": 0.0
        }
    ],
    "64172bb2690f196b5100001e_1": [
        {
            "start_logit": 7.84765625,
            "end_logit": 8.0,
            "text": "promoter sequences",
            "probability": 1.0
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -3.330078125,
            "text": "promoter",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -4.63671875,
            "end_logit": 8.0,
            "text": "RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.0,
            "text": "sequences",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -8.71875,
            "text": "promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.734375,
            "end_logit": 8.0,
            "text": ". RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 8.0,
            "text": "the maintenance and transmission of genetic information. RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 8.0,
            "text": "polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences",
            "probability": 0.0
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -10.0859375,
            "text": "promoter sequences and initiate transcription de novo and",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 8.0,
            "text": "transmission of genetic information. RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 8.0,
            "text": "(RNAPs) differ from other polymerases in that they can bind promoter sequences",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 8.0,
            "text": "RNAPs) differ from other polymerases in that they can bind promoter sequences",
            "probability": 0.0
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -10.6171875,
            "text": "promoter sequences and",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 8.0,
            "text": "and transmission of genetic information. RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 8.0,
            "text": "other polymerases in that they can bind promoter sequences",
            "probability": 0.0
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -11.5859375,
            "text": "promoter sequences and initiate transcription de novo",
            "probability": 0.0
        },
        {
            "start_logit": -4.63671875,
            "end_logit": -3.330078125,
            "text": "RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -3.330078125,
            "text": ". RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": -3.330078125,
            "text": "the maintenance and transmission of genetic information. RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter",
            "probability": 0.0
        },
        {
            "start_logit": -5.90625,
            "end_logit": -7.37890625,
            "text": "Polymerases are integral factors of gene expression and are essential for the maintenance and transmission of genetic information.",
            "probability": 0.0
        }
    ],
    "64172bb2690f196b5100001e_2": [
        {
            "start_logit": 16.234375,
            "end_logit": 17.4375,
            "text": "RNA polymerase II",
            "probability": 1.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -1.5,
            "text": "RNA polymerase II (pol II) paused within the proximal promoter region",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -1.6767578125,
            "text": "RNA polymerase II (pol II) paused within the proximal promoter",
            "probability": 0.0
        },
        {
            "start_logit": -3.201171875,
            "end_logit": 17.4375,
            "text": "II",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -3.2578125,
            "text": "RNA polymerase II (pol II) paused within the proximal",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -3.525390625,
            "text": "RNA",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -3.60546875,
            "text": "RNA polymerase II (pol II",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -4.53125,
            "text": "RNA polymerase II (pol II) pa",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -4.6484375,
            "text": "RNA polymerase II (pol II)",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -5.2109375,
            "text": "RNA polymerase",
            "probability": 0.0
        },
        {
            "start_logit": -6.734375,
            "end_logit": 17.4375,
            "text": "polymerase II",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -5.55078125,
            "text": "RNA polymerase II (pol II) paused within the",
            "probability": 0.0
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 17.4375,
            "text": "the RNA polymerase II",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -5.9296875,
            "text": "RNA polymerase II (pol II) paused within the proximal promoter region.",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": 17.4375,
            "text": "transcription factors trigger transcription by the RNA polymerase II",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -6.0546875,
            "text": "RNA polymerase II (",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 17.4375,
            "text": "transcription by the RNA polymerase II",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 17.4375,
            "text": "conventional transcription factors trigger transcription by the RNA polymerase II",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -7.140625,
            "text": "RNA polymerase II (pol",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -7.265625,
            "text": "RNA polymerase II (pol II) paused",
            "probability": 0.0
        }
    ],
    "64172bb2690f196b5100001e_3": [
        {
            "start_logit": 0.99169921875,
            "end_logit": 6.6640625,
            "text": "RNA polymerase is known to bind and utilize the overlapping promoters P1 and P2 in Escherichia coli galactose operon. We have identified an additional specific site upstream of P2",
            "probability": 0.662109375
        },
        {
            "start_logit": -0.281005859375,
            "end_logit": 6.6640625,
            "text": "upstream of P2",
            "probability": 0.1851806640625
        },
        {
            "start_logit": -0.93798828125,
            "end_logit": 6.6640625,
            "text": "promoters P1 and P2 in Escherichia coli galactose operon. We have identified an additional specific site upstream of P2",
            "probability": 0.0960693359375
        },
        {
            "start_logit": -1.705078125,
            "end_logit": 6.6640625,
            "text": "galactose operon. We have identified an additional specific site upstream of P2",
            "probability": 0.044677734375
        },
        {
            "start_logit": -3.814453125,
            "end_logit": 6.6640625,
            "text": "P2",
            "probability": 0.00542449951171875
        },
        {
            "start_logit": 0.99169921875,
            "end_logit": 1.734375,
            "text": "RNA polymerase is known to bind and utilize the overlapping promoters P1 and P2 in Escherichia coli galactose operon",
            "probability": 0.00478363037109375
        },
        {
            "start_logit": -0.93798828125,
            "end_logit": 1.734375,
            "text": "promoters P1 and P2 in Escherichia coli galactose operon",
            "probability": 0.0006952285766601562
        },
        {
            "start_logit": 0.99169921875,
            "end_logit": -0.381591796875,
            "text": "RNA polymerase is known to bind and utilize the overlapping promoters P1 and P2 in Escherichia coli galactose operon.",
            "probability": 0.000576019287109375
        },
        {
            "start_logit": -1.705078125,
            "end_logit": 1.734375,
            "text": "galactose operon",
            "probability": 0.0003230571746826172
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 6.6640625,
            "text": "in Escherichia coli galactose operon. We have identified an additional specific site upstream of P2",
            "probability": 0.0001285076141357422
        },
        {
            "start_logit": -0.93798828125,
            "end_logit": -0.381591796875,
            "text": "promoters P1 and P2 in Escherichia coli galactose operon.",
            "probability": 8.362531661987305e-05
        },
        {
            "start_logit": -8.140625,
            "end_logit": 6.6640625,
            "text": "of P2",
            "probability": 7.152557373046875e-05
        },
        {
            "start_logit": -8.484375,
            "end_logit": 6.6640625,
            "text": "site upstream of P2",
            "probability": 5.072355270385742e-05
        },
        {
            "start_logit": -8.5625,
            "end_logit": 6.6640625,
            "text": "P2 in Escherichia coli galactose operon. We have identified an additional specific site upstream of P2",
            "probability": 4.690885543823242e-05
        },
        {
            "start_logit": 0.99169921875,
            "end_logit": -2.92578125,
            "text": "RNA polymerase is known to bind and utilize the overlapping promoters P1 and P2 in Escherichia coli galactose operon. We have identified an additional specific site upstream",
            "probability": 4.51207160949707e-05
        },
        {
            "start_logit": -1.705078125,
            "end_logit": -0.381591796875,
            "text": "galactose operon.",
            "probability": 3.892183303833008e-05
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 6.6640625,
            "text": ". We have identified an additional specific site upstream of P2",
            "probability": 2.6524066925048828e-05
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 6.6640625,
            "text": "polymerase is known to bind and utilize the overlapping promoters P1 and P2 in Escherichia coli galactose operon. We have identified an additional specific site upstream of P2",
            "probability": 1.4901161193847656e-05
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 6.6640625,
            "text": "and P2 in Escherichia coli galactose operon. We have identified an additional specific site upstream of P2",
            "probability": 1.4662742614746094e-05
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 6.6640625,
            "text": "operon. We have identified an additional specific site upstream of P2",
            "probability": 1.4185905456542969e-05
        }
    ],
    "641790d6690f196b5100002d_0": [
        {
            "start_logit": 7.84375,
            "end_logit": 10.0625,
            "text": "between 7-13 years of age",
            "probability": 0.759765625
        },
        {
            "start_logit": 6.4296875,
            "end_logit": 10.0625,
            "text": "7-13 years of age",
            "probability": 0.1861572265625
        },
        {
            "start_logit": 7.84375,
            "end_logit": 7.19921875,
            "text": "between 7-13 years",
            "probability": 0.043548583984375
        },
        {
            "start_logit": 6.4296875,
            "end_logit": 7.19921875,
            "text": "7-13 years",
            "probability": 0.010498046875
        },
        {
            "start_logit": -0.95263671875,
            "end_logit": 10.0625,
            "text": "age",
            "probability": 0.00011479854583740234
        },
        {
            "start_logit": 7.84375,
            "end_logit": 0.2861328125,
            "text": "between 7",
            "probability": 4.32133674621582e-05
        },
        {
            "start_logit": 6.4296875,
            "end_logit": 0.2861328125,
            "text": "7",
            "probability": 1.049041748046875e-05
        },
        {
            "start_logit": -3.638671875,
            "end_logit": 10.0625,
            "text": "13 years of age",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": -4.05078125,
            "end_logit": 10.0625,
            "text": "years of age",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -5.04296875,
            "end_logit": 10.0625,
            "text": "of age",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 7.84375,
            "end_logit": -3.849609375,
            "text": "between 7-13",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -3.638671875,
            "end_logit": 7.19921875,
            "text": "13 years",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.8828125,
            "end_logit": 10.0625,
            "text": "X-linked recessive genetic disorder, that is characterized by progressive muscle degeneration and loss of ambulation between 7-13 years of age",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.05078125,
            "end_logit": 7.19921875,
            "text": "years",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 10.0625,
            "text": "DMD) is an X-linked recessive genetic disorder, that is characterized by progressive muscle degeneration and loss of ambulation between 7-13 years of age",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.4296875,
            "end_logit": -3.849609375,
            "text": "7-13",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.84375,
            "end_logit": -5.31640625,
            "text": "between 7-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 10.0625,
            "text": "-13 years of age",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 10.0625,
            "text": ") is an X-linked recessive genetic disorder, that is characterized by progressive muscle degeneration and loss of ambulation between 7-13 years of age",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.5859375,
            "end_logit": 10.0625,
            "text": "recessive genetic disorder, that is characterized by progressive muscle degeneration and loss of ambulation between 7-13 years of age",
            "probability": 5.960464477539063e-08
        }
    ],
    "6428da74690f196b51000052_0": [
        {
            "start_logit": 15.7578125,
            "end_logit": 15.1484375,
            "text": "Alternative splicing",
            "probability": 1.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -4.58203125,
            "text": "Alternative",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -5.26953125,
            "text": "Alternative splicing (AS)",
            "probability": 0.0
        },
        {
            "start_logit": -5.6875,
            "end_logit": 15.1484375,
            "text": "splicing",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -7.328125,
            "text": "Alternative splicing (",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -8.78125,
            "text": "Alternative splicing (AS",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -9.15625,
            "text": "Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome complexity remains elusive in plants.",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -10.328125,
            "text": "Alternative splicing (AS) generates multiple transcripts from the same gene",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -10.7109375,
            "text": "Alternative splicing (AS) generates multiple transcripts from the same gene, however,",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -10.75,
            "text": "Alternative splicing (AS) generates multiple transcripts from the same gene, however",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -10.7890625,
            "text": "Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome complexity",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -10.9765625,
            "text": "Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -11.046875,
            "text": "Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -11.25,
            "text": "Alternative splicing (AS) generates",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -11.421875,
            "text": "Alternative splicing (AS) generates multiple transcripts",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -11.6015625,
            "text": "Alternative splicing (AS) generates multiple transcripts from the same gene,",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -11.65625,
            "text": "Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome complexity remains elusive in",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -11.8125,
            "text": "Alternative splicing (AS) generates multiple",
            "probability": 0.0
        },
        {
            "start_logit": 15.7578125,
            "end_logit": -11.9921875,
            "text": "Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome complexity remains elusive in plants",
            "probability": 0.0
        },
        {
            "start_logit": -5.6875,
            "end_logit": -5.26953125,
            "text": "splicing (AS)",
            "probability": 0.0
        }
    ],
    "6428da74690f196b51000052_1": [
        {
            "start_logit": 10.65625,
            "end_logit": 9.796875,
            "text": "AS",
            "probability": 1.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -5.828125,
            "text": "AS not only to potentially increasing proteomic complexity, but also to buffer against the stress",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.65625,
            "end_logit": -6.390625,
            "text": "AS not only to potentially increasing proteomic complexity, but also to buffer against the stress-responsive transcriptome to reduce the metabolic cost of translating all AS transcripts.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.65625,
            "end_logit": -8.9453125,
            "text": "AS not only to potentially increasing proteomic complexity",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.796875,
            "text": "We propose that plants employ AS",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -9.5390625,
            "text": "AS not only to potentially increasing proteomic complexity, but also to buffer against the stress-responsive transcriptome",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -9.78125,
            "text": "AS not only to potentially increasing proteomic complexity,",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 9.796875,
            "text": "employ AS",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -10.5,
            "text": "AS not only to potentially increasing proteomic complexity, but also to buffer against the stress-responsive transcriptome to",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 9.796875,
            "text": "plants employ AS",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -10.9296875,
            "text": "AS not only to potentially increasing proteomic complexity, but also to buffer against the stress-responsive transcriptome to reduce the metabolic cost of translating",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 9.796875,
            "text": "that plants employ AS",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 9.796875,
            "text": "propose that plants employ AS",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -10.9921875,
            "text": "AS not only to potentially increasing proteomic complexity, but also to buffer",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -11.0625,
            "text": "AS not only to potentially increasing proteomic complexity, but also to buffer against the stress-responsive",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -11.09375,
            "text": "AS not",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -11.1875,
            "text": "AS not only to potentially increasing",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -11.203125,
            "text": "AS not only to potentially increasing proteomic complexity, but also to buffer against the stress-responsive transcriptome to reduce the metabolic cost of translating all AS",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -11.265625,
            "text": "AS not only to potentially",
            "probability": 0.0
        },
        {
            "start_logit": -2.802734375,
            "end_logit": -5.828125,
            "text": "stress",
            "probability": 0.0
        }
    ],
    "6428da74690f196b51000052_2": [
        {
            "start_logit": 15.9609375,
            "end_logit": 16.078125,
            "text": "Alternative splicing",
            "probability": 1.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -4.17578125,
            "text": "Alternative",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": 16.078125,
            "text": "splicing",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -5.58984375,
            "text": "Alternative splicing,",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -7.40625,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene,",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -8.546875,
            "text": "Alternative splicing, which",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -8.84375,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity and regulate mRNA levels.",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -10.09375,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -10.484375,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -10.75,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene, is",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -10.96875,
            "text": "Alternative splicing, which generates",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -11.0859375,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -11.1015625,
            "text": "Alternative splicing, which generates multiple transcripts",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -11.21875,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -11.296875,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -11.3203125,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity and regulate mRNA",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -11.34375,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -11.421875,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity and regulate mRNA levels",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -11.4296875,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -5.58984375,
            "text": "splicing,",
            "probability": 0.0
        }
    ],
    "6428da74690f196b51000052_3": [
        {
            "start_logit": 15.796875,
            "end_logit": 15.1640625,
            "text": "Alternative splicing",
            "probability": 1.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -4.51953125,
            "text": "Alternative",
            "probability": 0.0
        },
        {
            "start_logit": -5.5859375,
            "end_logit": 15.1640625,
            "text": "splicing",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -6.48046875,
            "text": "Alternative splicing,",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -6.9453125,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms,",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -9.0,
            "text": "Alternative splicing, which",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -10.2734375,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -10.8203125,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -10.84375,
            "text": "Alternative splicing, which generates",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -10.859375,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -10.875,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscription",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -10.890625,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional regulatory mechanism",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -10.9375,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -11.3671875,
            "text": "Alternative splicing, which generates multiple transcripts",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -11.484375,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional regulatory",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -11.5546875,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional regulatory mechanism for expanding proteomic diversity",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -11.7109375,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional regulatory mechanism for expanding proteomic",
            "probability": 0.0
        },
        {
            "start_logit": 15.796875,
            "end_logit": -11.7265625,
            "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional",
            "probability": 0.0
        },
        {
            "start_logit": -5.5859375,
            "end_logit": -6.48046875,
            "text": "splicing,",
            "probability": 0.0
        },
        {
            "start_logit": -5.5859375,
            "end_logit": -6.9453125,
            "text": "splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms,",
            "probability": 0.0
        }
    ],
    "64179aac690f196b51000037_0": [
        {
            "start_logit": 6.6796875,
            "end_logit": 14.6171875,
            "text": "1 years",
            "probability": 0.958984375
        },
        {
            "start_logit": 3.505859375,
            "end_logit": 14.6171875,
            "text": "28.1 years",
            "probability": 0.040191650390625
        },
        {
            "start_logit": -0.77099609375,
            "end_logit": 14.6171875,
            "text": "1990 have a median life expectancy of 28.1 years",
            "probability": 0.0005559921264648438
        },
        {
            "start_logit": -1.375,
            "end_logit": 14.6171875,
            "text": ".1 years",
            "probability": 0.0003044605255126953
        },
        {
            "start_logit": -3.671875,
            "end_logit": 14.6171875,
            "text": "median life expectancy of 28.1 years",
            "probability": 3.063678741455078e-05
        },
        {
            "start_logit": -4.1328125,
            "end_logit": 14.6171875,
            "text": "years",
            "probability": 1.9311904907226562e-05
        },
        {
            "start_logit": -5.62109375,
            "end_logit": 14.6171875,
            "text": "increased life expectancy in more recent patient populations; patients born after 1990 have a median life expectancy of 28.1 years",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 14.6171875,
            "text": "of 28.1 years",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 14.6171875,
            "text": "life expectancy of 28.1 years",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 14.6171875,
            "text": "a median life expectancy of 28.1 years",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.171875,
            "end_logit": 14.6171875,
            "text": "life expectancy in more recent patient populations; patients born after 1990 have a median life expectancy of 28.1 years",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 14.6171875,
            "text": "after 1990 have a median life expectancy of 28.1 years",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 14.6171875,
            "text": "patients born after 1990 have a median life expectancy of 28.1 years",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.6171875,
            "text": "expectancy of 28.1 years",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.6171875,
            "text": "recent patient populations; patients born after 1990 have a median life expectancy of 28.1 years",
            "probability": 0.0
        },
        {
            "start_logit": 3.505859375,
            "end_logit": -1.2900390625,
            "text": "28",
            "probability": 0.0
        },
        {
            "start_logit": 3.505859375,
            "end_logit": -2.099609375,
            "text": "28.",
            "probability": 0.0
        },
        {
            "start_logit": 6.6796875,
            "end_logit": -6.55078125,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -0.77099609375,
            "end_logit": -0.2666015625,
            "text": "1990",
            "probability": 0.0
        },
        {
            "start_logit": -0.77099609375,
            "end_logit": -1.2900390625,
            "text": "1990 have a median life expectancy of 28",
            "probability": 0.0
        }
    ],
    "6422ee03690f196b51000046_0": [
        {
            "start_logit": 14.359375,
            "end_logit": 15.28125,
            "text": "by erythroid precursors",
            "probability": 1.0
        },
        {
            "start_logit": 3.7109375,
            "end_logit": 15.28125,
            "text": "erythroid precursors",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": 14.359375,
            "end_logit": -0.221435546875,
            "text": "by erythroid precursors in response to erythropoietin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.19140625,
            "end_logit": 15.28125,
            "text": ". Erythroferrone, a factor produced and secreted by erythroid precursors",
            "probability": 0.0
        },
        {
            "start_logit": -5.49609375,
            "end_logit": 15.28125,
            "text": "precursors",
            "probability": 0.0
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 15.28125,
            "text": "secreted by erythroid precursors",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -5.69140625,
            "text": "by",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 15.28125,
            "text": "a factor produced and secreted by erythroid precursors",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 15.28125,
            "text": "produced and secreted by erythroid precursors",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 15.28125,
            "text": "factor produced and secreted by erythroid precursors",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 15.28125,
            "text": "Erythroferrone, a factor produced and secreted by erythroid precursors",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -6.9765625,
            "text": "by erythroid",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": 15.28125,
            "text": ", a factor produced and secreted by erythroid precursors",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.21875,
            "text": "by erythroid precursors in response to",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.140625,
            "text": "by erythroid precursors in response",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.953125,
            "text": "by erythroid precursors in response to erythropoietin,",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -10.5,
            "text": "by erythroid precursors in response to erythropoietin, has been identified and characterized as a suppressor of hepcidin",
            "probability": 0.0
        },
        {
            "start_logit": 3.7109375,
            "end_logit": -0.221435546875,
            "text": "erythroid precursors in response to erythropoietin",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -10.875,
            "text": "by erythroid precursors in",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -10.9765625,
            "text": "by erythroid precursors in response to erythropoietin, has been identified and characterized as a suppressor of hepcidin synthesis to allow iron",
            "probability": 0.0
        }
    ],
    "6422ee03690f196b51000046_1": [
        {
            "start_logit": 16.75,
            "end_logit": 16.921875,
            "text": "erythroid cells",
            "probability": 1.0
        },
        {
            "start_logit": 16.75,
            "end_logit": -1.7802734375,
            "text": "erythroid",
            "probability": 0.0
        },
        {
            "start_logit": -3.005859375,
            "end_logit": 16.921875,
            "text": "by erythroid cells",
            "probability": 0.0
        },
        {
            "start_logit": 16.75,
            "end_logit": -3.126953125,
            "text": "erythroid cells in response to hemorrhage, hypoxia, or other erythropoietic stimuli, and it suppresses the hepatic production of the iron-regulatory hormone hepcidin",
            "probability": 0.0
        },
        {
            "start_logit": -4.1015625,
            "end_logit": 16.921875,
            "text": "cells",
            "probability": 0.0
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 16.921875,
            "text": "The hormone erythroferrone (ERFE) is produced by erythroid cells",
            "probability": 0.0
        },
        {
            "start_logit": 16.75,
            "end_logit": -7.89453125,
            "text": "erythroid cells in response to hemorrhage, hypoxia, or other erythropoietic stimuli, and it suppresses the hepatic",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 16.921875,
            "text": "ERFE) is produced by erythroid cells",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 16.921875,
            "text": "FE) is produced by erythroid cells",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 16.921875,
            "text": "hormone erythroferrone (ERFE) is produced by erythroid cells",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 16.921875,
            "text": "produced by erythroid cells",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": 16.921875,
            "text": "is produced by erythroid cells",
            "probability": 0.0
        },
        {
            "start_logit": 16.75,
            "end_logit": -9.0,
            "text": "erythroid cells in response to",
            "probability": 0.0
        },
        {
            "start_logit": 16.75,
            "end_logit": -9.4921875,
            "text": "erythroid cells in response to hemorrhage, hypoxia, or other erythropo",
            "probability": 0.0
        },
        {
            "start_logit": 16.75,
            "end_logit": -9.5625,
            "text": "erythroid cells in response to hemorrhage, hypoxia, or other erythropoietic stimuli, and it suppresses the hepatic production of the iron-regulatory hormone",
            "probability": 0.0
        },
        {
            "start_logit": 16.75,
            "end_logit": -9.5859375,
            "text": "erythroid cells in response to hemorrhage, hypoxia, or other erythropoietic stimuli",
            "probability": 0.0
        },
        {
            "start_logit": 16.75,
            "end_logit": -9.765625,
            "text": "erythroid cells in",
            "probability": 0.0
        },
        {
            "start_logit": 16.75,
            "end_logit": -9.8359375,
            "text": "erythroid cells in response",
            "probability": 0.0
        },
        {
            "start_logit": 16.75,
            "end_logit": -9.8515625,
            "text": "erythroid cells in response to hemorrhage, hypoxia, or other erythropoietic stimuli, and it suppresses the hepatic production of the iron",
            "probability": 0.0
        },
        {
            "start_logit": -3.005859375,
            "end_logit": -1.7802734375,
            "text": "by erythroid",
            "probability": 0.0
        }
    ],
    "6422ee03690f196b51000046_2": [
        {
            "start_logit": 11.28125,
            "end_logit": 4.8515625,
            "text": "Erythroid",
            "probability": 1.0
        },
        {
            "start_logit": 11.28125,
            "end_logit": -3.09765625,
            "text": "Erythroid overproduction of erythroferrone causes iron",
            "probability": 0.0003571510314941406
        },
        {
            "start_logit": 11.28125,
            "end_logit": -4.13671875,
            "text": "Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice.",
            "probability": 0.00012540817260742188
        },
        {
            "start_logit": 11.28125,
            "end_logit": -8.265625,
            "text": "Erythroid overproduction",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 11.28125,
            "end_logit": -9.625,
            "text": "Erythroid overproduction of erythroferrone causes iron overload",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 11.28125,
            "end_logit": -11.1328125,
            "text": "Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.28125,
            "end_logit": -11.2265625,
            "text": "Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.28125,
            "end_logit": -11.3828125,
            "text": "Erythroid overproduction of erythroferrone causes iron overload and developmental",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.28125,
            "end_logit": -11.796875,
            "text": "Erythroid overproduction of erythroferrone causes iron overload and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.28125,
            "end_logit": -11.9921875,
            "text": "Erythroid overproduction of erythroferrone causes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.28125,
            "end_logit": -12.0234375,
            "text": "Erythroid overproduction of erythroferrone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.28125,
            "end_logit": -12.0859375,
            "text": "Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.484375,
            "end_logit": -3.09765625,
            "text": "iron",
            "probability": 0.0
        },
        {
            "start_logit": -4.484375,
            "end_logit": -4.13671875,
            "text": "iron overload and developmental abnormalities in mice.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": -3.09765625,
            "text": "erythroferrone causes iron",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -3.09765625,
            "text": "overproduction of erythroferrone causes iron",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -3.09765625,
            "text": "of erythroferrone causes iron",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -3.09765625,
            "text": "rone causes iron",
            "probability": 0.0
        },
        {
            "start_logit": -4.484375,
            "end_logit": -9.625,
            "text": "iron overload",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": -3.09765625,
            "text": "ferrone causes iron",
            "probability": 0.0
        }
    ],
    "6422ee03690f196b51000046_3": [
        {
            "start_logit": 14.2109375,
            "end_logit": 13.53125,
            "text": "hepatocytes",
            "probability": 1.0
        },
        {
            "start_logit": -6.203125,
            "end_logit": 13.53125,
            "text": "by erythroblasts, acts on hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 13.53125,
            "text": "erythroblasts, acts on hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -8.65625,
            "end_logit": 13.53125,
            "text": "blasts, acts on hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.8046875,
            "text": "hepatocytes to suppress hepcidin production, and thereby increase dietary iron",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": 13.53125,
            "text": "ts, acts on hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 13.53125,
            "text": "produced by erythroblasts, acts on hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 13.53125,
            "text": ", produced by erythroblasts, acts on hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 13.53125,
            "text": "hormone erythroferrone, produced by erythroblasts, acts on hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -10.703125,
            "text": "hepatocytes to suppress hepcidin",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -10.7578125,
            "text": "hepatocytes to suppress hepcidin production, and thereby increase dietary iron absorption and mobilization from stores.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 13.53125,
            "text": "the hormone erythroferrone, produced by erythroblasts, acts on hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 13.53125,
            "text": "erythroferrone, produced by erythroblasts, acts on hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -11.0546875,
            "text": "hepatocytes to suppress",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 13.53125,
            "text": "rone, produced by erythroblasts, acts on hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 13.53125,
            "text": "on hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -11.859375,
            "text": "hepatocytes to suppress hepcidin production, and thereby increase",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -11.875,
            "text": "hepatocytes to",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -11.9140625,
            "text": "hepatocytes to suppress hepcidin production, and thereby increase dietary iron absorption",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -11.953125,
            "text": "hepatocytes to suppress hepcidin production,",
            "probability": 0.0
        }
    ],
    "6415c0df690f196b51000010_0": [
        {
            "start_logit": 15.453125,
            "end_logit": 16.140625,
            "text": "Fragment-based drug discovery",
            "probability": 1.0
        },
        {
            "start_logit": -3.958984375,
            "end_logit": 16.140625,
            "text": "discovery",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -5.1796875,
            "text": "Fragment",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -5.515625,
            "text": "Fragment-based drug",
            "probability": 0.0
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 16.140625,
            "text": "drug discovery",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -6.390625,
            "text": "Fragment-",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -6.5078125,
            "text": "Fragment-based drug discovery (FBDD)",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -7.0546875,
            "text": "Fragment-based",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 16.140625,
            "text": "-based drug discovery",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 16.140625,
            "text": "based drug discovery",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -9.3671875,
            "text": "Fragment-based drug discovery (",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -9.375,
            "text": "Fragment-based drug discovery (FBDD) has",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -10.0625,
            "text": "Fragment-based drug discovery (FBDD",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -10.234375,
            "text": "Fragment-based drug discovery (FB",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -10.5546875,
            "text": "Fragment-based drug discovery (FBDD) has grown",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -10.5703125,
            "text": "Fragment-based drug discovery (FBDD) has grown and matured",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -11.578125,
            "text": "Fragment-based drug discovery (FBDD) has grown and matured to a point",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -11.8046875,
            "text": "Fragment-based drug discovery (FBDD) has grown and matured to a point where it is valuable to keep track of its extent and details of application",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -11.84375,
            "text": "Fragment-based drug discovery (FBDD) has grown and matured to a",
            "probability": 0.0
        },
        {
            "start_logit": 15.453125,
            "end_logit": -11.9140625,
            "text": "Fragment-based drug discovery (FBDD) has grown and matured to a point where it is valuable to keep track of its extent",
            "probability": 0.0
        }
    ],
    "6412331b201352f04a000038_0": [
        {
            "start_logit": 11.0234375,
            "end_logit": 12.5390625,
            "text": "Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that hijack the cell's ubiquitin-proteasome system (UPS).",
            "probability": 1.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 12.5390625,
            "text": "bifunctional molecules that hijack the cell's ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -6.35546875,
            "text": "Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that hijack the cell's ubiquitin-proteasome system",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 12.5390625,
            "text": "hijack the cell's ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -6.5703125,
            "text": "Proteolysis-targeting chimeras",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 12.5390625,
            "text": "-targeting chimeras (PROTACs) are bifunctional molecules that hijack the cell's ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": 12.5390625,
            "text": "targeting chimeras (PROTACs) are bifunctional molecules that hijack the cell's ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": -8.6328125,
            "end_logit": 12.5390625,
            "text": "chimeras (PROTACs) are bifunctional molecules that hijack the cell's ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": 12.5390625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 12.5390625,
            "text": "ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 12.5390625,
            "text": "(PROTACs) are bifunctional molecules that hijack the cell's ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 12.5390625,
            "text": "proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 12.5390625,
            "text": "are bifunctional molecules that hijack the cell's ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -8.4296875,
            "text": "Proteolysis-",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 12.5390625,
            "text": "jack the cell's ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 12.5390625,
            "text": "molecules that hijack the cell's ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -8.9140625,
            "text": "Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that hijack the cell's ubiquitin-proteasome system (",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 12.5390625,
            "text": "system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 12.5390625,
            "text": "that hijack the cell's ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 12.5390625,
            "text": "ck the cell's ubiquitin-proteasome system (UPS).",
            "probability": 0.0
        }
    ],
    "6415c8f1690f196b51000017_0": [
        {
            "start_logit": 14.375,
            "end_logit": 13.859375,
            "text": "TNBC",
            "probability": 1.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 13.859375,
            "text": "against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -9.2421875,
            "end_logit": 13.859375,
            "text": "therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 13.859375,
            "text": "Food and Drug Administration (FDA)-approved therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 13.859375,
            "text": "FDA)-approved therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 13.859375,
            "text": "Paclitaxel, docetaxel, doxorubicin, and epirubicin have been longstanding, Food and Drug Administration (FDA)-approved therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 13.859375,
            "text": "longstanding, Food and Drug Administration (FDA)-approved therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 13.859375,
            "text": "epirubicin have been longstanding, Food and Drug Administration (FDA)-approved therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 13.859375,
            "text": "approved therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 13.859375,
            "text": "Administration (FDA)-approved therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 13.859375,
            "text": ")-approved therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 13.859375,
            "text": "doxorubicin, and epirubicin have been longstanding, Food and Drug Administration (FDA)-approved therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 13.859375,
            "text": "have been longstanding, Food and Drug Administration (FDA)-approved therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 13.859375,
            "text": "and epirubicin have been longstanding, Food and Drug Administration (FDA)-approved therapies against TNBC",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -11.1015625,
            "text": "TNBC.",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -10.2890625,
            "text": "against",
            "probability": 0.0
        },
        {
            "start_logit": -9.2421875,
            "end_logit": -10.2890625,
            "text": "therapies against",
            "probability": 0.0
        },
        {
            "start_logit": -9.2421875,
            "end_logit": -10.484375,
            "text": "therapies",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -10.2890625,
            "text": "Food and Drug Administration (FDA)-approved therapies against",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -11.1015625,
            "text": "against TNBC.",
            "probability": 0.0
        }
    ],
    "63eeec79f36125a426000006_0": [
        {
            "start_logit": 16.65625,
            "end_logit": 16.25,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": 16.65625,
            "end_logit": -2.5078125,
            "text": "multiple",
            "probability": 0.0
        },
        {
            "start_logit": -4.4921875,
            "end_logit": 16.25,
            "text": "myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 16.65625,
            "end_logit": -8.90625,
            "text": "multiple myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 16.25,
            "text": "BCMA levels in patients with relapsed/refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": 16.25,
            "text": "soluble BCMA levels in patients with relapsed/refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 16.25,
            "text": "talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 16.25,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.640625,
            "end_logit": 16.25,
            "text": "with relapsed/refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 16.25,
            "text": "MA levels in patients with relapsed/refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 16.25,
            "text": "b on soluble BCMA levels in patients with relapsed/refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 16.25,
            "text": "Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 16.25,
            "text": "teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 16.25,
            "text": "relapsed/refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 16.25,
            "text": "tamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -2.5078125,
            "text": "BCMA levels in patients with relapsed/refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": -2.5078125,
            "text": "soluble BCMA levels in patients with relapsed/refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -2.5078125,
            "text": "talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -2.5078125,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.640625,
            "end_logit": -2.5078125,
            "text": "with relapsed/refractory multiple",
            "probability": 0.0
        }
    ],
    "63eeec79f36125a426000006_1": [
        {
            "start_logit": 14.859375,
            "end_logit": 13.1484375,
            "text": "MM",
            "probability": 1.0
        },
        {
            "start_logit": 14.859375,
            "end_logit": -10.28125,
            "text": "MM.",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 13.1484375,
            "text": "for MM",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 13.1484375,
            "text": "G protein-coupled receptor family C group 5 member D [GPRC5D]\u00d7CD3) are in clinical development as therapies for MM",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 13.1484375,
            "text": "therapies for MM",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 13.1484375,
            "text": "receptor family C group 5 member D [GPRC5D]\u00d7CD3) are in clinical development as therapies for MM",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 13.1484375,
            "text": "in clinical development as therapies for MM",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 13.1484375,
            "text": "CD3) are in clinical development as therapies for MM",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 13.1484375,
            "text": "clinical development as therapies for MM",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": -10.28125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": -10.28125,
            "text": "for MM.",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": -10.28125,
            "text": "G protein-coupled receptor family C group 5 member D [GPRC5D]\u00d7CD3) are in clinical development as therapies for MM.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -10.28125,
            "text": "therapies for MM.",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -10.28125,
            "text": "receptor family C group 5 member D [GPRC5D]\u00d7CD3) are in clinical development as therapies for MM.",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": -10.28125,
            "text": "in clinical development as therapies for MM.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -10.28125,
            "text": "CD3) are in clinical development as therapies for MM.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": -10.8671875,
            "text": "talquetamab (G protein-coupled receptor family C group 5 member D [GPRC5D",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -10.8671875,
            "text": "BCMA\u00d7CD3) and talquetamab (G protein-coupled receptor family C group 5 member D [GPRC5D",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -10.28125,
            "text": "clinical development as therapies for MM.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": -11.2421875,
            "text": "talquetamab (G protein-coupled receptor family C group 5 member D [GPRC5D]\u00d7CD3",
            "probability": 0.0
        }
    ],
    "6422e2f1690f196b51000043_0": [
        {
            "start_logit": 12.734375,
            "end_logit": 14.8671875,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -5.57421875,
            "end_logit": 14.8671875,
            "text": "Most siRNA therapeutic efforts to date have focused on the treatment of liver",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": 14.8671875,
            "text": "siRNA therapeutic efforts to date have focused on the treatment of liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": 14.8671875,
            "text": "efforts to date have focused on the treatment of liver",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -7.19921875,
            "text": "liver diseases due to major breakthroughs in the development of efficient strategies for delivering siRNA drugs to the liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 14.8671875,
            "text": "the treatment of liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 14.8671875,
            "text": "date have focused on the treatment of liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 14.8671875,
            "text": "to date have focused on the treatment of liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 14.8671875,
            "text": "have focused on the treatment of liver",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -8.5625,
            "text": "liver diseases",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -10.0625,
            "text": "liver diseases due to major breakthroughs in the development of efficient strategies for delivering siRNA drugs to the liver. Indeed, the development of lipid nanoparticle-",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -11.0625,
            "text": "liver diseases due to major breakthroughs in the development of efficient strategies for delivering siRNA drugs to the liver. Indeed, the development of lipid nanoparticle-formulated",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -11.3125,
            "text": "liver diseases due to major breakthroughs in the development of efficient strategies for delivering",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -11.359375,
            "text": "liver diseases due to major breakthroughs in the development of efficient strategies for delivering siRNA drugs to the liver. Indeed, the development of lipid nanoparticle",
            "probability": 0.0
        },
        {
            "start_logit": -5.5703125,
            "end_logit": -6.78125,
            "text": "porphyr",
            "probability": 0.0
        },
        {
            "start_logit": -5.5703125,
            "end_logit": -7.76953125,
            "text": "porphyria",
            "probability": 0.0
        },
        {
            "start_logit": -5.57421875,
            "end_logit": -8.5625,
            "text": "Most siRNA therapeutic efforts to date have focused on the treatment of liver diseases",
            "probability": 0.0
        },
        {
            "start_logit": -5.57421875,
            "end_logit": -10.5625,
            "text": "Most siRNA therapeutic efforts to date have",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -6.78125,
            "text": "transthyretin amyloidosis and givosiran for the treatment of acute hepatic porphyr",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": -7.19921875,
            "text": "efforts to date have focused on the treatment of liver diseases due to major breakthroughs in the development of efficient strategies for delivering siRNA drugs to the liver",
            "probability": 0.0
        }
    ],
    "6422e2f1690f196b51000043_1": [
        {
            "start_logit": 13.515625,
            "end_logit": 14.53125,
            "text": "hepatocytes",
            "probability": 1.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": 14.53125,
            "text": "liver hepatocytes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 14.53125,
            "text": "siRNA conjugation with a targeting moiety for liver hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 14.53125,
            "text": "for liver hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 14.53125,
            "text": "targeting moiety for liver hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 14.53125,
            "text": "Food and Drug Administration and the European Medicines Agency between 2018 and 2022. These are mainly based on an siRNA conjugation with a targeting moiety for liver hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 14.53125,
            "text": "an siRNA conjugation with a targeting moiety for liver hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 14.53125,
            "text": "Drug Administration and the European Medicines Agency between 2018 and 2022. These are mainly based on an siRNA conjugation with a targeting moiety for liver hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 14.53125,
            "text": "conjugation with a targeting moiety for liver hepatocytes",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -11.03125,
            "text": "hepatocytes, N-acetylgalactosamine",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -11.7734375,
            "text": "hepatocytes, N-acetylgalactosamine,",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -4.109375,
            "text": "liver",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -11.03125,
            "text": "liver hepatocytes, N-acetylgalactosamine",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -11.7734375,
            "text": "liver hepatocytes, N-acetylgalactosamine,",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -4.109375,
            "text": "siRNA conjugation with a targeting moiety for liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -4.109375,
            "text": "for liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": -4.109375,
            "text": "targeting moiety for liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -4.109375,
            "text": "Food and Drug Administration and the European Medicines Agency between 2018 and 2022. These are mainly based on an siRNA conjugation with a targeting moiety for liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": -4.109375,
            "text": "US Food and Drug Administration and the European Medicines Agency between 2018 and 2022. These are mainly based on an siRNA conjugation with a targeting moiety for liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -4.109375,
            "text": "an siRNA conjugation with a targeting moiety for liver",
            "probability": 0.0
        }
    ],
    "6422e2f1690f196b51000043_2": [
        {
            "start_logit": -6.125,
            "end_logit": 10.9765625,
            "text": "asialoglycoprotein receptor (ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.8115234375
        },
        {
            "start_logit": -8.625,
            "end_logit": 10.9765625,
            "text": "GalNAc-conjugated siRNAs rapidly distribute into the liver via asialoglycoprotein receptor (ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.06658935546875
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 10.9765625,
            "text": "hepatocytes",
            "probability": 0.03826904296875
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 10.9765625,
            "text": "glycoprotein receptor (ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.01428985595703125
        },
        {
            "start_logit": -10.203125,
            "end_logit": 10.9765625,
            "text": "the hepatocytes",
            "probability": 0.01374053955078125
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 10.9765625,
            "text": "receptor (ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.006145477294921875
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 10.9765625,
            "text": "uptake in the hepatocytes",
            "probability": 0.00577545166015625
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 10.9765625,
            "text": "oprotein receptor (ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.005687713623046875
        },
        {
            "start_logit": -11.09375,
            "end_logit": 10.9765625,
            "text": "ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.00563812255859375
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 10.9765625,
            "text": "liver via asialoglycoprotein receptor (ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.005340576171875
        },
        {
            "start_logit": -11.1796875,
            "end_logit": 10.9765625,
            "text": "loglycoprotein receptor (ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.005176544189453125
        },
        {
            "start_logit": -11.234375,
            "end_logit": 10.9765625,
            "text": "(ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.0048980712890625
        },
        {
            "start_logit": -11.3046875,
            "end_logit": 10.9765625,
            "text": "siRNAs rapidly distribute into the liver via asialoglycoprotein receptor (ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.00457000732421875
        },
        {
            "start_logit": -11.3125,
            "end_logit": 10.9765625,
            "text": "via asialoglycoprotein receptor (ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.0045318603515625
        },
        {
            "start_logit": -11.4296875,
            "end_logit": 10.9765625,
            "text": "mediated uptake in the hepatocytes",
            "probability": 0.0040283203125
        },
        {
            "start_logit": -11.4609375,
            "end_logit": 10.9765625,
            "text": "conjugated siRNAs rapidly distribute into the liver via asialoglycoprotein receptor (ASGPR) mediated uptake in the hepatocytes",
            "probability": 0.00390625
        },
        {
            "start_logit": -6.125,
            "end_logit": -7.3125,
            "text": "asialoglycoprotein receptor",
            "probability": 0.0
        },
        {
            "start_logit": -6.125,
            "end_logit": -8.375,
            "text": "asialoglycoprotein receptor (ASGP",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": -7.3125,
            "text": "GalNAc-conjugated siRNAs rapidly distribute into the liver via asialoglycoprotein receptor",
            "probability": 0.0
        },
        {
            "start_logit": -6.125,
            "end_logit": -9.8828125,
            "text": "asialoglycoprotein receptor (ASGPR) mediated uptake",
            "probability": 0.0
        }
    ],
    "6422e2f1690f196b51000043_3": [
        {
            "start_logit": 9.53125,
            "end_logit": 9.625,
            "text": "liver",
            "probability": 0.9990234375
        },
        {
            "start_logit": 2.52734375,
            "end_logit": 9.625,
            "text": "hree such products (givosiran, lumasiran and inclisiran) are liver",
            "probability": 0.0009107589721679688
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 9.625,
            "text": "ee such products (givosiran, lumasiran and inclisiran) are liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.52734375,
            "end_logit": -1.7470703125,
            "text": "hr",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -10.1171875,
            "text": "liver-targeted, using tris N-acetylgalactosamine (GalNAc)3",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 9.625,
            "text": "products (givosiran, lumasiran and inclisiran) are liver",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -10.9140625,
            "text": "liver-targeted,",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 9.625,
            "text": "lumasiran and inclisiran) are liver",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 9.625,
            "text": "such products (givosiran, lumasiran and inclisiran) are liver",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -10.984375,
            "text": "liver-targeted, using tris N-acetylgalactosamine",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -11.015625,
            "text": "liver-targeted, using tris N-acetylgalactosamine (GalNAc",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -11.0703125,
            "text": "liver-targeted",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 9.625,
            "text": "givosiran, lumasiran and inclisiran) are liver",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -11.2265625,
            "text": "liver-targeted, using tris N-acetylgalactosamine (GalNAc)3 as the targeting ligand",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -11.390625,
            "text": "liver-",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -11.4765625,
            "text": "liver-targeted, using tris N-acetylgalactosamine (GalNAc)3 as the targeting ligand. Upon subcutaneous administration,",
            "probability": 0.0
        },
        {
            "start_logit": 2.52734375,
            "end_logit": -7.09765625,
            "text": "hree",
            "probability": 0.0
        },
        {
            "start_logit": 2.52734375,
            "end_logit": -9.640625,
            "text": "hree such products (givosiran",
            "probability": 0.0
        },
        {
            "start_logit": 2.52734375,
            "end_logit": -9.734375,
            "text": "hree such",
            "probability": 0.0
        },
        {
            "start_logit": 2.52734375,
            "end_logit": -10.8671875,
            "text": "hree such products (givosiran, lumasiran and inclisiran",
            "probability": 0.0
        }
    ],
    "6422e2f1690f196b51000043_4": [
        {
            "start_logit": 14.4140625,
            "end_logit": 14.03125,
            "text": "transthyretin",
            "probability": 1.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": 4.32421875,
            "text": "transthyretin in murine primary hepatocytes",
            "probability": 6.109476089477539e-05
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -5.51171875,
            "text": "trans",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -5.80859375,
            "text": "transthy",
            "probability": 0.0
        },
        {
            "start_logit": -5.77734375,
            "end_logit": 14.03125,
            "text": "retin",
            "probability": 0.0
        },
        {
            "start_logit": -6.0703125,
            "end_logit": 14.03125,
            "text": "thyretin",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 14.03125,
            "text": "GalNAc-conjugated siRNAs with bulges at certain positions of the guide strand repress transthyretin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -9.6875,
            "text": "transthyretin in",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 14.03125,
            "text": "siRNAs with bulges at certain positions of the guide strand repress transthyretin",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 14.03125,
            "text": "repress transthyretin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -10.6328125,
            "text": "transthyretin in murine primary hepatocytes and in vivo in mice.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 14.03125,
            "text": "strand repress transthyretin",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.03125,
            "text": "guide strand repress transthyretin",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.03125,
            "text": "bulges at certain positions of the guide strand repress transthyretin",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 14.03125,
            "text": "we show that GalNAc-conjugated siRNAs with bulges at certain positions of the guide strand repress transthyretin",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 14.03125,
            "text": "conjugated siRNAs with bulges at certain positions of the guide strand repress transthyretin",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 14.03125,
            "text": "certain positions of the guide strand repress transthyretin",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 14.03125,
            "text": ", we show that GalNAc-conjugated siRNAs with bulges at certain positions of the guide strand repress transthyretin",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.03125,
            "text": "the guide strand repress transthyretin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -11.9921875,
            "text": "transthyretin in murine primary hepatocytes and",
            "probability": 0.0
        }
    ],
    "6429ad3857b1c7a315000003_0": [
        {
            "start_logit": 1.7158203125,
            "end_logit": 5.85546875,
            "text": "Xist encodes a long noncoding RNA",
            "probability": 0.9951171875
        },
        {
            "start_logit": -4.0390625,
            "end_logit": 5.85546875,
            "text": "long noncoding RNA",
            "probability": 0.003154754638671875
        },
        {
            "start_logit": -4.84375,
            "end_logit": 5.85546875,
            "text": "RNA",
            "probability": 0.00141143798828125
        },
        {
            "start_logit": -6.125,
            "end_logit": 5.85546875,
            "text": "a long noncoding RNA",
            "probability": 0.0003917217254638672
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 5.85546875,
            "text": "noncoding RNA",
            "probability": 0.00013589859008789062
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 5.85546875,
            "text": "st encodes a long noncoding RNA",
            "probability": 6.473064422607422e-05
        },
        {
            "start_logit": 1.7158203125,
            "end_logit": -7.78515625,
            "text": "Xist",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 1.7158203125,
            "end_logit": -8.140625,
            "text": "Xist encodes a long noncoding RNA which",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 1.7158203125,
            "end_logit": -8.4453125,
            "text": "Xist encodes a long",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 1.7158203125,
            "end_logit": -8.6796875,
            "text": "Xi",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 1.7158203125,
            "end_logit": -8.921875,
            "text": "Xist encodes a long noncoding RNA which is a central player to induce X-chromosome inactivation in female mammals and has",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 1.7158203125,
            "end_logit": -10.5078125,
            "text": "Xist encodes a long noncoding",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.0390625,
            "end_logit": -8.140625,
            "text": "long noncoding RNA which",
            "probability": 0.0
        },
        {
            "start_logit": -4.0390625,
            "end_logit": -8.4453125,
            "text": "long",
            "probability": 0.0
        },
        {
            "start_logit": -4.0390625,
            "end_logit": -8.921875,
            "text": "long noncoding RNA which is a central player to induce X-chromosome inactivation in female mammals and has",
            "probability": 0.0
        },
        {
            "start_logit": -4.84375,
            "end_logit": -8.140625,
            "text": "RNA which",
            "probability": 0.0
        },
        {
            "start_logit": -4.84375,
            "end_logit": -8.6953125,
            "text": "RNA which is a central player to induce X-chromosome inactivation in female mammals and has two major splicing variants: long and short isoforms of Xist",
            "probability": 0.0
        },
        {
            "start_logit": -4.84375,
            "end_logit": -8.921875,
            "text": "RNA which is a central player to induce X-chromosome inactivation in female mammals and has two major splicing variants: long and short isoforms of Xist RNA",
            "probability": 0.0
        },
        {
            "start_logit": -4.84375,
            "end_logit": -8.921875,
            "text": "RNA which is a central player to induce X-chromosome inactivation in female mammals and has",
            "probability": 0.0
        },
        {
            "start_logit": -4.0390625,
            "end_logit": -10.1953125,
            "text": "long noncoding RNA which is a central player to induce X-chromosome inactivation in female mammals and has two major splicing variants: long and short isoforms of Xi",
            "probability": 0.0
        }
    ],
    "6429ad3857b1c7a315000003_1": [
        {
            "start_logit": -0.873046875,
            "end_logit": -1.001953125,
            "text": "X",
            "probability": 0.67822265625
        },
        {
            "start_logit": -1.73828125,
            "end_logit": -1.001953125,
            "text": "XIST encodes a spliced noncoding polyadenylated transcript that is unique in being expressed exclusively from the inactive X",
            "probability": 0.285400390625
        },
        {
            "start_logit": -4.97265625,
            "end_logit": -1.001953125,
            "text": "a spliced noncoding polyadenylated transcript that is unique in being expressed exclusively from the inactive X",
            "probability": 0.0112152099609375
        },
        {
            "start_logit": -5.71875,
            "end_logit": -1.001953125,
            "text": "the inactive X",
            "probability": 0.005344390869140625
        },
        {
            "start_logit": -1.73828125,
            "end_logit": -4.9921875,
            "text": "XIST encodes a spliced noncoding polyadenylated transcript",
            "probability": 0.005279541015625
        },
        {
            "start_logit": -0.873046875,
            "end_logit": -6.5390625,
            "text": "X chromosome",
            "probability": 0.0026645660400390625
        },
        {
            "start_logit": -6.44921875,
            "end_logit": -1.001953125,
            "text": "transcript that is unique in being expressed exclusively from the inactive X",
            "probability": 0.0025634765625
        },
        {
            "start_logit": -1.73828125,
            "end_logit": -6.03125,
            "text": "XI",
            "probability": 0.0018672943115234375
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -1.001953125,
            "text": "spliced noncoding polyadenylated transcript that is unique in being expressed exclusively from the inactive X",
            "probability": 0.0012693405151367188
        },
        {
            "start_logit": -7.171875,
            "end_logit": -1.001953125,
            "text": "inactive X",
            "probability": 0.0012493133544921875
        },
        {
            "start_logit": -1.73828125,
            "end_logit": -6.5390625,
            "text": "XIST encodes a spliced noncoding polyadenylated transcript that is unique in being expressed exclusively from the inactive X chromosome",
            "probability": 0.0011196136474609375
        },
        {
            "start_logit": -7.703125,
            "end_logit": -1.001953125,
            "text": "noncoding polyadenylated transcript that is unique in being expressed exclusively from the inactive X",
            "probability": 0.0007338523864746094
        },
        {
            "start_logit": -1.73828125,
            "end_logit": -7.2421875,
            "text": "XIST",
            "probability": 0.0005540847778320312
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.001953125,
            "text": "polyadenylated transcript that is unique in being expressed exclusively from the inactive X",
            "probability": 0.0004420280456542969
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -1.001953125,
            "text": "ylated transcript that is unique in being expressed exclusively from the inactive X",
            "probability": 0.00040221214294433594
        },
        {
            "start_logit": -1.73828125,
            "end_logit": -7.6953125,
            "text": "XIST encodes a spliced noncoding polyadenylated transcript that is unique in being expressed exclusively from the",
            "probability": 0.0003523826599121094
        },
        {
            "start_logit": -8.484375,
            "end_logit": -1.001953125,
            "text": "ST encodes a spliced noncoding polyadenylated transcript that is unique in being expressed exclusively from the inactive X",
            "probability": 0.0003364086151123047
        },
        {
            "start_logit": -8.59375,
            "end_logit": -1.001953125,
            "text": "is unique in being expressed exclusively from the inactive X",
            "probability": 0.000301361083984375
        },
        {
            "start_logit": -0.873046875,
            "end_logit": -8.9921875,
            "text": "X chromosome and is involved in the X-inactivation process.",
            "probability": 0.00022923946380615234
        },
        {
            "start_logit": -1.73828125,
            "end_logit": -8.1484375,
            "text": "XIST encodes a spliced noncoding polyadenylated transcript that is unique in being expressed exclusively from the inactive",
            "probability": 0.0002238750457763672
        }
    ],
    "6429ad3857b1c7a315000003_2": [
        {
            "start_logit": 7.5,
            "end_logit": 8.890625,
            "text": "X",
            "probability": 1.0
        },
        {
            "start_logit": -2.82421875,
            "end_logit": 8.890625,
            "text": "XIST encodes a functional RNA that is expressed exclusively from the inactive X",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": -3.892578125,
            "end_logit": 8.890625,
            "text": "RNA that is expressed exclusively from the inactive X",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -5.21484375,
            "end_logit": 8.890625,
            "text": "the inactive X",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 8.890625,
            "text": "inactive X",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 8.890625,
            "text": "functional RNA that is expressed exclusively from the inactive X",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.171875,
            "end_logit": 8.890625,
            "text": "a functional RNA that is expressed exclusively from the inactive X",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.2265625,
            "end_logit": 8.890625,
            "text": "ST encodes a functional RNA that is expressed exclusively from the inactive X",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5,
            "end_logit": -10.5546875,
            "text": "X in female mammals and is required for the silencing of most of the genes on the chromosome.",
            "probability": 0.0
        },
        {
            "start_logit": 7.5,
            "end_logit": -10.734375,
            "text": "X in female mammals and is",
            "probability": 0.0
        },
        {
            "start_logit": 7.5,
            "end_logit": -10.90625,
            "text": "X in female mammals and",
            "probability": 0.0
        },
        {
            "start_logit": -2.82421875,
            "end_logit": -7.30078125,
            "text": "XIST encodes a functional RNA",
            "probability": 0.0
        },
        {
            "start_logit": -3.892578125,
            "end_logit": -7.30078125,
            "text": "RNA",
            "probability": 0.0
        },
        {
            "start_logit": -2.82421875,
            "end_logit": -8.3984375,
            "text": "XIST encodes a functional RNA that is expressed exclusively from the inactive",
            "probability": 0.0
        },
        {
            "start_logit": -2.82421875,
            "end_logit": -8.5,
            "text": "XIST",
            "probability": 0.0
        },
        {
            "start_logit": -2.82421875,
            "end_logit": -8.5234375,
            "text": "XI",
            "probability": 0.0
        },
        {
            "start_logit": -2.82421875,
            "end_logit": -9.2734375,
            "text": "XIST encodes a functional RNA that is expressed exclusively from the",
            "probability": 0.0
        },
        {
            "start_logit": -3.892578125,
            "end_logit": -8.3984375,
            "text": "RNA that is expressed exclusively from the inactive",
            "probability": 0.0
        },
        {
            "start_logit": -2.82421875,
            "end_logit": -9.9921875,
            "text": "XIST encodes a functional RNA that",
            "probability": 0.0
        },
        {
            "start_logit": -3.892578125,
            "end_logit": -9.2734375,
            "text": "RNA that is expressed exclusively from the",
            "probability": 0.0
        }
    ],
    "6429ad3857b1c7a315000003_3": [
        {
            "start_logit": -2.49609375,
            "end_logit": -1.169921875,
            "text": "X",
            "probability": 0.6455078125
        },
        {
            "start_logit": -3.220703125,
            "end_logit": -1.169921875,
            "text": "one X",
            "probability": 0.31298828125
        },
        {
            "start_logit": -3.220703125,
            "end_logit": -3.916015625,
            "text": "one",
            "probability": 0.02008056640625
        },
        {
            "start_logit": -2.49609375,
            "end_logit": -5.484375,
            "text": "X chromosome",
            "probability": 0.0086517333984375
        },
        {
            "start_logit": -3.220703125,
            "end_logit": -5.484375,
            "text": "one X chromosome",
            "probability": 0.004184722900390625
        },
        {
            "start_logit": -7.7109375,
            "end_logit": -1.169921875,
            "text": "Dosage compensation in mammals is achieved by the transcriptional inactivation of one X",
            "probability": 0.0034942626953125
        },
        {
            "start_logit": -8.421875,
            "end_logit": -1.169921875,
            "text": "inactivation of one X",
            "probability": 0.00171661376953125
        },
        {
            "start_logit": -8.5625,
            "end_logit": -1.169921875,
            "text": "transcriptional inactivation of one X",
            "probability": 0.001491546630859375
        },
        {
            "start_logit": -2.49609375,
            "end_logit": -7.6171875,
            "text": "X chromosome in female cells.",
            "probability": 0.0010251998901367188
        },
        {
            "start_logit": -3.220703125,
            "end_logit": -7.6171875,
            "text": "one X chromosome in female cells.",
            "probability": 0.0004954338073730469
        },
        {
            "start_logit": -7.7109375,
            "end_logit": -3.916015625,
            "text": "Dosage compensation in mammals is achieved by the transcriptional inactivation of one",
            "probability": 0.00022518634796142578
        },
        {
            "start_logit": -8.421875,
            "end_logit": -3.916015625,
            "text": "inactivation of one",
            "probability": 0.000110626220703125
        },
        {
            "start_logit": -8.5625,
            "end_logit": -3.916015625,
            "text": "transcriptional inactivation of one",
            "probability": 9.614229202270508e-05
        },
        {
            "start_logit": -7.06640625,
            "end_logit": -5.484375,
            "text": "chromosome",
            "probability": 8.958578109741211e-05
        },
        {
            "start_logit": -7.7109375,
            "end_logit": -5.484375,
            "text": "Dosage compensation in mammals is achieved by the transcriptional inactivation of one X chromosome",
            "probability": 4.684925079345703e-05
        },
        {
            "start_logit": -8.421875,
            "end_logit": -5.484375,
            "text": "inactivation of one X chromosome",
            "probability": 2.300739288330078e-05
        },
        {
            "start_logit": -8.5625,
            "end_logit": -5.484375,
            "text": "transcriptional inactivation of one X chromosome",
            "probability": 1.996755599975586e-05
        },
        {
            "start_logit": -7.06640625,
            "end_logit": -7.6171875,
            "text": "chromosome in female cells.",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -7.7109375,
            "end_logit": -7.6171875,
            "text": "Dosage compensation in mammals is achieved by the transcriptional inactivation of one X chromosome in female cells.",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -7.6171875,
            "text": ".",
            "probability": 3.2782554626464844e-06
        }
    ],
    "6429ad3857b1c7a315000003_4": [
        {
            "start_logit": -0.59765625,
            "end_logit": -0.89306640625,
            "text": "X",
            "probability": 0.94287109375
        },
        {
            "start_logit": -0.59765625,
            "end_logit": -4.0859375,
            "text": "X chromosome",
            "probability": 0.0386962890625
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -0.89306640625,
            "text": "the inactive X",
            "probability": 0.01454925537109375
        },
        {
            "start_logit": -0.59765625,
            "end_logit": -7.453125,
            "text": "X chromosome coincides with the acquisition of a multitude of chromatin modifications, resulting in the formation of extraordinarily stable facultative heterochromatin",
            "probability": 0.0013427734375
        },
        {
            "start_logit": -7.453125,
            "end_logit": -0.89306640625,
            "text": "inactive X",
            "probability": 0.0009975433349609375
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -4.0859375,
            "text": "the inactive X chromosome",
            "probability": 0.0005955696105957031
        },
        {
            "start_logit": -4.37109375,
            "end_logit": -4.6953125,
            "text": "X",
            "probability": 0.00048613548278808594
        },
        {
            "start_logit": -7.453125,
            "end_logit": -4.0859375,
            "text": "inactive X chromosome",
            "probability": 4.082918167114258e-05
        },
        {
            "start_logit": -4.2109375,
            "end_logit": -7.56640625,
            "text": "RNA",
            "probability": 3.2007694244384766e-05
        },
        {
            "start_logit": -4.37109375,
            "end_logit": -7.56640625,
            "text": "X chromosome known as the X-inactivation center, which contains the Xist gene and its cis-regulatory elements. Xist encodes an RNA",
            "probability": 2.7418136596679688e-05
        },
        {
            "start_logit": -7.890625,
            "end_logit": -4.0859375,
            "text": "chromosome",
            "probability": 2.6345252990722656e-05
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -7.37109375,
            "text": "the",
            "probability": 2.2351741790771484e-05
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -7.453125,
            "text": "the inactive X chromosome coincides with the acquisition of a multitude of chromatin modifications, resulting in the formation of extraordinarily stable facultative heterochromatin",
            "probability": 2.0682811737060547e-05
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -8.2109375,
            "text": "the inactive",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -8.390625,
            "end_logit": -4.6953125,
            "text": "The integration of all these processes requires a region of the X",
            "probability": 8.702278137207031e-06
        },
        {
            "start_logit": -4.37109375,
            "end_logit": -8.71875,
            "text": "X chromosome known as the X-inactivation center, which contains the Xist gene and its cis-regulatory elements. Xist",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": -5.70703125,
            "end_logit": -7.56640625,
            "text": "Xist encodes an RNA",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -4.2109375,
            "end_logit": -9.2578125,
            "text": "RNA molecule that plays critical roles in the choice of which X chromosome remains active, and in the initial spread and establishment of silencing on the inactive X",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -4.6953125,
            "text": "heterochromatin that is faithfully propagated through subsequent cell divisions. The integration of all these processes requires a region of the X",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -4.6953125,
            "text": "the X",
            "probability": 4.589557647705078e-06
        }
    ]
}
